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5-FC  5-fluorocytosine 
5-FU  5-fluorouracil 
5-FUMP  5-fluorouridine monophosphate  
Ad  adenovirus 
AAT  antiangiogenic therapies 
bp  base pair 
CAR  coxsackie-adenovirus receptor 
CCL5  chemokine (C-C motif) ligand 5 
CD  cytosine deaminase 
Cox-2  cyclooxygenase-2 
CMV  cytomegalovirus 
CR  constant region 
CRAd  conditionally replicating adenovirus 
CSC  cancer stem cells 
CT   computerized Axial Tomography Scan  
CTLA-4  cytotoxic T Lymphocyte-Associated Antigen 4  
CTL  cytotoxic T-lymphocytes 
DLT  dose limited toxicity 
DMEM   dulbecco’s modified Eagle’s medium 
DNA  deoxyribonucleic acid 
DNAPK  DNA-protein kinase 
DSB  double strand brakes 
EGFR  epidermal growth factor receptor  
EpCAM  epithelial cell adhesion molecule 
FACS  fluorescence activated cell sorting 
FCS  fetal calf serum 
FCU1  bifunctional fusion enzyme of CD and UPRT 
Foxp3  forkhead box p3 
GCV  ganciclovir 
GM   growth media 
GM-CSF  granulocyte macrophage colony-stimulating factor 
Gy  gray 
HCC  hepatocellular carcinoma 
HeLa  Henrietta Lacks tumor cells 
HIFU  high-intensity focused ultrasound 
HNC  head and neck cancer 
HNSCC  head and neck squamous cell carcinoma 
HPV  human papillomavirus 
HSV-TK  herpes simplex thymidine kinase 
HSPGs  heparin sulfate proteoglycans 
hTERT  human telomerase 
IFN  interferon 
i.ha.  intrahepatic artery 
IMRT  intensity-modulated radiation therapy 
i.p.  intraperitoneal 
irAEs  immune-related adverse events 
i.t.  intratumoral 
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ITR  inverted terminal repeat 
i.v.  intravenous 
LacZ  β-galactosidase 
luc  luciferase 
mAb  monoclonal antibody 
MAP  mitomycin C + doxorubicin + cisplatin 
miRNAs  microRNAs 
MHC  major histocompatibility complex 
MMPs  matrix metalloproteinases 
MOI  multiplicity of infection 
MRI   magnetic resonance imaging 
NF-κB  nuclear factor κB 
NK  natural killer cells 
NKT  natural killer T cells 
OV  oncolytic virotherapy 
PBMC  peripheral blood mononuclear cell  
PBS  phosphate buffered saline 
PC  prostate carcinoma 
PCR  polymerase chain reaction 
PET   positron emission tomography 
PET-CT  positron emission tomography - computed tomography 
PFU  plaque forming unit 
pK  polylysine 
PMA  phorbol myristyl acetate 
pRb  retinoblastoma protein family 
Rb  retinoblastoma 
RISC  RNA-induced silencing complex 
RNA  ribonucleic acid 
RGD  arginine-glycine-aspartic acid 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNAs  small interfering RNAs 
TCID50  tissue culture infective dose 50 
TCR   T cell receptor 
TGF-β   transforming growth factor beta 
TH3  T helper type-3 cells 
TKI  tyrosine kinase inhibitor 
T-regs  regulatory T cells 
TSPs  tissue-specific promoters 
UPRT  uracil phosphoribosyltransferase 
VDR  vitamin D receptor 
VEGF  vascular endothelial growth factor 
VEGFR  vascular endothelial growth factor receptor 




Advanced stage head and neck cancers (HNC) with distant metastasis, as well as prostate 
cancers (PC), are devastating diseases currently lacking efficient treatment options. One 
promising developmental approach in cancer treatment is the use of oncolytic adenoviruses, 
especially in combination therapy with conventional cancer therapies. The safety of the 
approach has been tested in many clinical trials. However, antitumor efficacy needs to be 
improved in order to establish oncolytic viruses as a viable treatment alternative. To be able 
to test in vivo the effects on anti-tumor efficiency of a multimodal combination therapy of 
oncolytic adenoviruses with the standard therapeutic combination of radiotherapy, 
chemotherapy and Cetuximab monoclonal antibody (mAb), a xenograft HNC tumor model 
was developed. This model mimics the typical clinical situation as it is initially sensitive to 
cetuximab, but resistance develops eventually. Surprisingly, but in agreement with recent 
findings for chemotherapy and radiotherapy, a higher proportion of cells positive for HNC 
cancer stem cell markers were found in the tumors refractory to cetuximab. In vitro as well 
as in vivo results found in this study support the multimodal combination therapy of oncolytic 
adenoviruses with chemotherapy, radiotherapy and monoclonal antibody therapy to achieve 
increased anti-tumor efficiency and even complete tumor eradication with lower treatment 
doses required. In this study, it was found that capsid modified oncolytic viruses have 
increased gene transfer to cancer cells as well as an increased antitumor effect. In order to 
elucidate the mechanism of how oncolytic viruses promote radiosensitization of tumor cells 
in vivo, replicative deficient viruses expressing several promising radiosensitizing viral 
proteins were tested. The results of this study indicated that oncolytic adenoviruses promote 
radiosensitization by delaying the repair of DNA double strand breaks in tumor cells. Based 
on the promising data of the first study, two tumor double-targeted oncolytic adenoviruses 
armed with the fusion suicide gene FCU1 or with a fully human mAb specific for human 
Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) were produced. FCU1 encodes a 
bifunctional fusion protein that efficiently catalyzes the direct conversion of 5-FC, a relatively 
nontoxic antifungal agent, into the toxic metabolites 5-fluorouracil and 5-fluorouridine 
monophosphate, bypassing the natural resistance of certain human tumor cells to 5-
fluorouracil. Anti-CTLA4 mAb promotes direct killing of tumor cells via apoptosis and most 
importantly immune system activation against the tumors. These armed oncolytic viruses 
present increased anti-tumor efficacy both in vitro and in vivo. Furthermore, by taking 
advantage of the unique tumor targeted gene transfer of oncolytic adenoviruses, functional 
high tumor titers but low systemic concentrations of the armed proteins were generated. In 
addition, supernatants of tumor cells infected with Ad5/3-Δ24aCTLA4, which contain anti-
CTLA4 mAb, were able to effectively immunomodulate peripheral blood mononuclear cells 
(PBMC) of cancer patients with advanced tumors. 
In conclusion, the results presented in this thesis suggest that genetically engineered 
oncolytic adenoviruses have great potential in the treatment of advanced and metastatic 
HNC and PC.  
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PART B 
1 REVIEW OF THE LITERATURE 
1.1 Introduction 
Cancer is a devastating disease which has been one of the main known causes of death 
worldwide (Eaton 2003). Despite the improvements made in recent years in conventional 
cancer treatment modalities, together with more effective diagnostic techniques and earlier 
access to cancer treatments, the number of cancer cases is still on the rise (Eaton 2003). 
The high rates of mortality associated with cancer and the complications that arise with its 
treatments has encouraged the pursuit of alternative therapeutic strategies. 
In recent years, developments in the fields of cancer biology, cancer genetics and molecular 
biology have stimulated a renewed interest in cancer gene therapy with special interest in 
tumor targeted oncolytic viruses. Several viruses have been used in the past few years 
(Vähä-Koskela, Heikkilä et al. 2007) but by far adenoviruses are the most studied and to the 
present day the only approved vector for the treatment of cancer patients (Garber 2006). 
Several clinical trials have demonstrated the safety of oncolytic viruses as well as promising 
results in anti-tumor efficacy (Nemunaitis, Khuri et al. 2001; Xia, Chang et al. 2004; Yu and 
Fang 2007). The most promising results were obtained with modalities in combination with 
conventional therapies. However, antitumor efficacy needs to be improved in order to 
establish oncolytic viruses as a viable treatment alternative. 
 
1.2 Cancer 
Cancer is a major public health problem in many parts of the world (Eaton 2003). It has been 
projected that cancer will become the leading cause of death worldwide this year in World 
Cancer Report from the International Agency for Research on Cancer. Furthermore, cancer 
has the most devastating economic impact of any cause of death in the world according to 
the Global Economic Cost of Cancer Report authored by Dr. Rigo John and Dr.Hana Ross 
(American Cancer Society and LIVESTRONG®). In 2002, 10.9 million new cases, 6.7 million 
related deaths and 24.6 million persons alive with cancer (within three years of diagnosis) 
were reported worldwide (Parkin, Bray et al. 2005). The most recent reports estimate that in 
Europe there are 1.7 million cancer related deaths every year alone (Ferlay, Parkin et al. 
2010). Furthermore, the World Health Organization expects that the worldwide number of 
newly diagnosed cancers will double to 20 million by 2020, unless preventive measures are 
taken (Eaton 2003). 
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1.2.1 Head and Neck Cancer 
Each year, more than 635,000 new cases of head and neck cancer (HNC) are diagnosed 
worldwide with 350 000 related deaths every year (Ferlay, Shin et al. 2010). HNC is the 
seventh most common cancer type worldwide, with more than 48,000 new cases reported 
every year in the United States alone (Ferlay, Shin et al. 2010; Jemal, Siegel et al. 2010). 
The incidence trends are declining in the last decade in the Indian subcontinent, East Asia, 
Western Europe and the United States for men, but for women, it is generally stable. In the 
Nordic countries, the incidence of HNC continues to increase for both men and women 
(Curado and Hashibe 2009). In Finland, only larynx or lip cancers have shown a decrease in 
incidence (Curado and Hashibe 2009). The major known risk factors are alcohol and 
tobacco consumption, but recently, the role of human papillomavirus (HPV) 16 in HNC, 
especially for oropharyngeal cancers, has been reported (Curado and Hashibe 2009). 
According to the latest cancer registries, in the developed countries 1 in 100 persons will be 
diagnosed with HNC during their life time and 1 out of 3 diagnosed cases will succumb to the 
disease (Curado and Hashibe 2009; Jemal, Siegel et al. 2009).  
 
1.2.1.1 Head and Neck Squamous Cell Carcinoma  
Approximately 90% of HNC cases are squamous cell carcinomas (HNSCC). HNSCC arises 
in the mucosal lining of the upper aerodigestive tract and it is an umbrella term that includes 
cancers at several sites (e.g. oral cavity, pharynx and larynx) having different etiologies and 
prognoses while sharing common risk factors and treatment options (Baatenburg de Jong, 
Hermans et al. 2001). The addition of chemotherapy to radiotherapy has been useful in the 
context of organ preservation. However, despite advances in conventional therapy including 
surgery, chemotherapy, and radiation, the 5-year mortality rate of patients with HNSCC has 
not improved (Prince and Ailles 2008). Uncontrolled growth, resulting from dramatic changes 
in gene expression patterns, combined with the relative accessibility of head and neck 
tumors to direct inoculation make HNSCC an ideal candidate for gene therapy approaches 
(Thomas and Grandis 2009). 
 
1.2.1.1.1 Molecular mechanisms of HNSCC  
Cascades of several genetic events promoting the inactivation of tumor-suppressor genes 
and/or activation of proto-oncogenes drive HNSCC progression. Molecular techniques have 
uncovered several genetic and epigenetic alterations in several stages of disease 
progression (Califano, van der Riet et al. 1996; Ha and Califano 2006; Perez-Ordonez, 
Beauchemin et al. 2006). The main risk factors associated with HNSCC are alcohol, tobacco 
consumption, and/or more recently oncogenic human papillomavirus type 16 (HPV16) 
exposure; disease occurs as a consequence of their genotoxic activity (Argiris, Karamouzis 
et al. 2008). Telomerase, which is involved in telomere maintenance and immortalization, 
thus protecting the acquired genetic changes, has been found to be reactivated in 90% of 
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HNSCC cases and in premalignant lesions (McCaul, Gordon et al. 2002). The loss of 9p21 is 
seen in 70–80% of HNSCC (Mao, Lee et al. 1996). Inactivation of p16, which is caused by 
homozygous deletion, point mutations, or promoter hypermethylation, and loss of 3p, could 
be early events in HNSCC carcinogenesis (Argiris, Karamouzis et al. 2008). Loss of 
heterozygosity of 17p and p53 point mutations are seen in over 50% of HNSCC cases (Balz, 
Scheckenbach et al. 2003). The prognostic significance of p53 mutations is rather 
controversial; however, disruptive p53 mutations in the DNA of the tumor were shown to be 
associated with reduced survival after surgical treatment of HNSCC (Argiris, Karamouzis et 
al. 2008). Amplification of 11q13 and over-expression of cyclin D1 are also detected in 
HNSCC, and could correlate with more aggressive tumor behavior (Argiris, Karamouzis et al. 
2008). 
 
1.2.1.1.2 Treatment options for HNSCC 
Currently, the standard of care for HNSCC combines surgery, radiotherapy, 
chemoradiotherapy and cetuximab. Standard therapy for local disease is surgery, often 
followed by radiation. Another option is chemoradiation instead of surgery. For locally 
advanced tumors, the operation can be followed by chemoradiation or radiation with 
cetuximab. For metastatic disease, chemotherapy + cetuximab is standard treatment 
modality. Surgery is a standard treatment for HNSCC but is frequently limited by the 
anatomical extent of the tumor and desire to achieve organ preservation. Advances in 
microsurgical free tissue transfer for reconstruction of surgical defects have made major 
reconstructive procedures commonplace at many centers, helping in the resection of locally 
advanced tumors. By use of modern surgical techniques, substantially improved functional 
outcomes are often possible for patients who need extensive surgical resections, even in the 
setting of salvage surgery after failure of organ-preserving treatment (Argiris, Karamouzis et 
al. 2008).  
The mortality rates and the morbid side effects associated with the standard therapies of 
HNSCC have prompted the pursuit of novel therapies. Therefore, in recent years, molecular 
targeted agents have been extensively studied and clinically tested in HNCs. These 
molecular targeted agents mainly centered on epidermal growth factor receptor (EGFR) 
inhibitors and antiangiogenic therapies (AAT), which include the modulation of vascular 
endothelial growth factor (VEGF) or its receptor (VEGFR). Examples of EGFR inhibitors 
include monoclonal antibodies against the extracellular domain of this receptor (e.g., 
cetuximab and panitumumab) and receptor tyrosine kinase inhibitors (TKIs) that target the 
intracellular domain (e.g., gefitinib and erlotinib). Other promising agents that produce 
antitumor effects in conjunction with EGFR receptor inhibitors include trastuzumab and 
lapatinib. Vandetanib, an antagonist of both VEGFR and the EGFR is in phase II trials. New 
molecular targets like hypoxia-inducible factor 1 alpha, mesenchymal-epithelial transition 
factor, insulin-like growth factor or the PI3K/AKT/mTOR pathway are currently under 
investigation. 
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 1.2.1.1.2.1 Radiation therapy 
Radiotherapy is an integral part of primary or adjuvant treatment of HNSCC. Radiotherapy 
alone results in high tumor control and cure rates for early stage glottic, base of tongue, and 
tonsillar cancers (Ding, Newman et al. 2005; Voynov, Heron et al. 2006). Advances in 
imaging and radiation delivery have dramatically changed management approaches. 
Planning CT scans are now frequently combined with diagnostic CT, MRI, or PET datasets 
to improve tumor delineation in three dimensions. Additional advances in radiotherapy 
include tomotherapy (integration of CT or PET-CT technology into a linear accelerator) 
heavy particle radiation, proton therapy, neutron beam radiation, brachytherapy, and 
stereotactic radiosurgery; however, in most instances these methods have not been 
validated in prospective randomized clinical trials (Ding, Newman et al. 2005; Voynov, Heron 
et al. 2006).  
Intensity modulated radiotherapy (IMRT) is an advanced approach to three-dimensional 
treatment planning and conformal therapy. It optimizes the delivery of irradiation to 
irregularly-shaped volumes and has the ability to produce concavities in radiation treatment 
volumes. When treating HNCs, IMRT allows for a greater sparing of normal structures such 
as salivary glands, upper aero-digestive tract mucosa, optic nerves, cochlea, pharyngeal 
constrictors, brain stem and spinal cord (Bhide and Nutting 2010). Salivary gland sparing 
using IMRT in various head and neck sub-sites has been demonstrated in randomized and 
non-randomised trials (Bhide and Nutting 2010). 
Radiation therapy for treatment of HNSCC is typically given in daily fractions of 2·0 Gy, 5 
days a week, up to a total dose of 70 Gy over 7 weeks. Long-term interruptions to 
radiotherapy or delays in starting postoperative radiotherapy are potentially harmful, 
presumably because of repopulation of cancer cells (Bentzen 2003; Suwinski, Sowa et al. 
2003; Bese, Hendry et al. 2007). Phase III trials have showed that despite of the 
improvements in locoregional control with increased infield toxic effects, the survival rates of 
hyperfractionation radiotherapy staid the same compared with conventional radiotherapy 
(Fu, Pajak et al. 2000).  
Ionizing radiation targets primarily DNA molecules and produces an array of lesions that 
include single-strand breaks, base alterations, oxidative damage and double-strand breaks 
(Li, Story et al. 2001).  
1.2.1.1.2.2 Chemotherapy 
The role of chemotherapy in HNSCC treatment has evolved from palliative care to a central 
component of curative programs for locally advanced HNSCC (Cohen, Lingen et al. 2004). 
Several classes of agents such as platinum compounds, antimetabolites and taxanes have 
shown single-agent activity against HNSCC (Colevas 2006). The platinum compound 
cisplatin is regarded as a standard agent in combination with radiation or with other agents.  
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The main biochemical mechanism of action of cisplatin involves the binding of the drug to 
DNA in the cell nucleus and subsequent interference with normal transcription, and/or DNA 
replication mechanisms. If cisplatin-DNA adducts are not efficiently processed by cell 
machinery, cytotoxic processes may result in cell death (Fuertesa, Castillab et al. 2003). 
However, there are also other possible mechanisms that may play a role in the activity of 
cisplatin. Even before cell entry, cisplatin can bind to phospholipids and phosphatidylserine 
in the cell membrane thereby triggering the Fas death receptor pathway, promoting cell 
death via apoptosis (Rebillard, Lagadic-Gossmann et al. 2008). Once inside the cell, 
cisplatin has a number of possible targets: DNA; RNA; sulfur-containing enzymes such as 
metallothionein and glutathione; and mitochondria (Pil and Lippard 1992). 
5-Fluorouracil (5-FU) is a pyrimidine analog that requires cellular uptake and metabolic 
activation in order to exert cytotoxicity. Routinely in the clinic, 5-FU is used in combined 
regimens with Cisplatin (Kish, Ensley et al. 1985). As a uracil analog, it serves as a substrate 
for the same transport processes and enzymes involved in anabolism and catabolism. As 
such, 5-FU may be utilized by several metabolic routes where it will be converted to its 
active metabolites for inhibition of DNA and RNA synthesis and interference with DNA repair 
(Grem 2000; Noordhuis, Holwerda et al. 2004). 
1.2.1.1.2.3 Monoclonal antibody therapy 
Epidermal growth factor receptor (EGFR) inhibition has emerged as a novel treatment 
strategy for HNSCC, and the monoclonal antibody cetuximab is the first EGFR targeted 
agent that has been introduced into standard practice (Karamouzis, Grandis et al. 2007). 
Other ways of targeting EGFR and other deregulated molecular pathways in HNSCC, using 
monoclonal antibodies, single-selective or multi-selective tyrosine kinase inhibitors, and 
nucleic acid-directed approaches, are also being explored (Argiris, Karamouzis et al. 2008). 
The combination of EGFR inhibitors with other molecularly targeted agents (e.g., 
angiogenesis inhibitors) has surfaced as a novel strategy, whereas the combination of these 
novel agents with chemotherapy and radiotherapy is under investigation (Argiris, 
Karamouzis et al. 2008). In our days, combination of cetuximab with either chemotherapy or 
radiotherapy is standard care and the triple combination is undergoing investigation. 
Monoclonal EGFR inhibiting antibodies have improved the efficacy of conventional 
chemotherapy in both pre-clinical and clinical studies. Although such therapies may lead to a 
partial response or disease stabilization in some patients, many patients do not benefit from 
EGFR inhibitor therapy. Even those who do, eventually develop resistance (Pao, Miller et al. 
2005). Great interest therefore exists in elucidating resistance mechanisms for EGFR 
inhibitor therapy. The molecular mechanisms of resistance can be attributed to several 
general processes involving emergence of inhibitor insensitive cell populations: (a) 
resistance due to the activation of alternative tyrosine kinase receptors that bypass the 
EGFR pathway (e.g. c-Met and IGF-1R), (b) resistance due to increased angiogenesis, (c) 
resistance based on constitutive activation of downstream mediators (e.g. PTEN, K-ras and 
others), (d) the existence of specific EGFR mutations (Dempke and Heinemann 2009) and 
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(e) emergence of EGFR negative clones. Therefore, combination treatments may be useful 
for avoiding development of EGFR inhibitor resistant disease. 
The mechanisms through which cetuximab expresses its antitumor activity are numerous 
and not completely understood in humans. The main cetuximab activities include the direct 
inhibition of EGFR tyrosine kinase activity, the inhibition of cell cycle progression, 
angiogenesis, invasion and metastasization, the increase and activation of pro-apoptotic 
molecules, and the synergic cytotoxicity with chemotherapy and radiotherapy (Vincenzi, 
Schiavon et al. 2008). In addition, cetuximab is able to induce antibody-dependent cell-
mediated cytotoxicity (Bonner, Harari et al. 2006). Moreover, recent reports suggest that 
cetuximab is able to also mediate complement system activation (Hsu, Ajona et al. 2010). 
1.2.1.1.3 Cancer stem cells 
Tumor initiating cells or cancer stem cells (CSC) are defined as cells that have the capacity 
to self-renew and to cause the heterogeneous lineages of cells that comprise the tumor 
(Reya, Morrison et al. 2001). Currently, there are two hypothetical explanations for the 
existence of CSCs. CSCs may arise from normal stem cells by mutation of genes that render 
the stem cells cancerous. Or, they may come from differentiated tumor cells that experience 
further genetic alterations and, therefore, become dedifferentiated and acquire CSC-like 
features (Chen 2009). According to the CSC theory, only a specific subpopulation of cancer 
cells called CSC have unlimited replicative potential and therefore the ability to sustain 
cancer growth. All of the other cancer cells or progenitor cells have a limited growth potential 
or no growth potential at all. Four key characteristics define the CSC subpopulation: (1) only 
a small portion of the cancer cells within a tumor have tumorigenic potential when 
transplanted into immunodeficient mice; (2) the CSC subpopulation can be separated from 
the other cancer cells by distinctive cell surface markers; (3) tumors resulting from the CSCs 
contain the mixed tumorigenic and non-tumorigenic cells of the original tumor; and (4) the 
CSC subpopulation can be serially transplanted through multiple generations, indicating that 
it is a self-renewing population (Prince and Ailles 2008).  
CSC have been suggested to represent a distinct subpopulation of cells in many human 
tumors including HNSCC (Prince, Sivanandan et al. 2007), while more differentiated and 
less tumorigenic cells constitute the bulk of tumor cells (Reya, Morrison et al. 2001). Several 
CSC markers have been reported for isolation of CSC, including CD133, CD44, ALDH1A1, 
and epithelial cell adhesion molecule (EpCAM) (Visvader and Lindeman 2008). However, 
there is no universal CSC marker for all types of cancer. Tumor initiating HNSCC cells have 
been proposed to present a distinct phenotype identifiable by surface markers CD44, CD133 
(Zhou, Wei et al. 2007; Pries, Witrkopf et al. 2008; Prince and Ailles 2008).  
CSC have many properties that separate them from mature, differentiated cells. In addition 
to their ability to self-renew and differentiate, they are quiescent, dividing infrequently. They 
also require specific environments comprising other cells, stroma and growth factors for their 
survival (Blanpain, Lowry et al. 2004). One particularly intriguing property of stem cells is that 
they express high levels of specific ABC drug transporters (Blanpain, Lowry et al. 2004). An 
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important implication of this concept is that cancer stem cells by their quiescence, their 
capacity for DNA repair, and ABC-transporter expression are possibly more resistant to 
treatment with drugs or radiation that preferentially kill fast replicating cells, which can lead to 
tumor regrowth and relapse (Dean, Fojo et al. 2005).  
1.2.2 Prostate cancer 
Prostate carcinoma (PC) is the second most frequently diagnosed cancer of men (914,000 
new cases, 13.8% of the total) and the fifth most common cancer overall (Ferlay, Shin et al. 
2010). In 2008, it is estimated that there were more than 258,000 PC related deaths. A rising 
incidence is observed mainly due to early detection programs and increasing of life 
expectancy (Allen, Howard et al. 2007). In 2008, in Europe alone there were 382,000 new 
cases diagnosed, placing PC as the fourth most common cancer type in Europe (Ferlay, 
Parkin et al. 2010). 
 
1.2.2.1 Molecular mechanisms in Prostate Cancer 
Data suggest that prostate cancer results from the successive accumulation of gene 
mutations (Vogelstein and Kinzler 2004). Linkage analyses have indicated several 
chromosomal loci, such as 1p36 (CABP) (Gibbs, Stanford et al. 1999), 1q24-q25 (HPC1) 
(Smith, Freije et al. 1996), 1q42.4-q43 (PCAP) (Berthon, Valeri et al. 1998), 8p22-23 (Xu, 
Zheng et al. 2001), 16q23 (Suarez, Lin et al. 2000), 17p12-p13 (Tavtigian, Simard et al. 
2001), 19q13 (Witte, Goddard et al. 2000), 20q13 (HPC20) (Berry, Schroeder et al. 2000), 
and Xq27-q28 (HPCX) (Xu, Meyers et al. 1998) that may harbor high-penetrance prostate 
cancer susceptibility genes. However, none of the loci have been verified indisputably by a 
second independent study confirming the tremendous heterogeneity in the predisposition of 
prostate cancer (Porkka and Visakorpi 2004). Three candidate susceptibility genes have 
also been identified. The first positionally cloned prostate cancer susceptibility gene was 
HPC2/ELAC2, located at 17p12 (Tavtigian, Simard et al. 2001). However, the function of the 
protein code by HPC2/ELAC2 is still not fully characterized. The second putative 
susceptibility gene was identified in HPC1-linked (chromosomal region 1q24-q25) families 
(Carpten, Nupponen et al. 2002). The prostate tumors carrying this mutated gene have 
reduced RNASEL enzyme activity. RNASEL is an endoribonuclease involved in the 
mediation of the antiviral and proapoptotic activities of the interferon-regulated 2-5A system 
(Porkka and Visakorpi 2004). The third identified prostate cancer susceptibility gene is the 
macrophage scavenger receptor 1 (MSR1) gene, located at 8p22-23 (Xu, Zheng et al. 
2002). The expression of MSR1 is induced in macrophages by oxidative stress. It has been 
suggested that the cancer predisposing effects of MSR1 is mediated by macrophages (Xu, 
Zheng et al. 2002; DeMarzo, Nelson et al. 2003).  
Numerous polymorphisms in many genes have already been suggested to be associated 
with the risk of prostate cancer (DeMarzo, Nelson et al. 2003; Gronberg 2003). Maybe the 
most widely studied polymorphic gene is the androgen receptor gene or genes that are 
involved in androgen metabolism. Other genes, whose sequence variations have been 
‐ 11 ‐ 
suggested to be associated with the risk of prostate cancer, include BRCA2 (Edwards, Kote-
Jarai et al. 2003), CHECK2 (Dong, Wang et al. 2003), vitamin D receptor (VDR) (Ingles, 
Ross et al. 1997), 17α-hydroxylase (CYP17) (Lunn, Bell et al. 1999), paraoxonase 1 (PON1) 
(Marchesani, Hakkarainen et al. 2003) and 5α reductase (SRD5A2) (Makridakis, Ross et al. 
1999). However, larger and better controlled studies are needed for more definitive 
associations. 
 
1.2.2.2 Treatment options for Prostate Cancer 
Radiotherapy and surgery are commonly used primary therapies for localized and locally 
advanced prostate cancer, with or without androgen deprivation therapy, and are the two 
main curative treatment options for PC (Shelley, Kumar et al. 2009). Radiation therapy may 
be delivered through external beam irradiation or brachytherapy. The choice of the curative 
treatment modality remains strongly related to patient features (age, urinary, digestive, 
sexual status) as well as tumor features such as Gleason score, clinical stage and PSA level 
(D'Amico, Whittington et al. 1998). Due to technical improvements, effects of radiotherapy in 
normal tissue are decreasing, and hence, important side effects such as erectile dysfunction 
or radiation proctitis are lowered, increasing the popularity of this therapeutic approach 
(Sanda, Dunn et al. 2008; Zelefsky, Levin et al. 2008). Also, great improvements have been 
achieved in radiotherapy dose planning, which has allowed higher tumor doses which leads 
to more cures. However, 35% of cases recur or are detected when metastatic (Pound, Partin 
et al. 1999). Hormonal therapies are usually effective initially, but given enough time, 
hormone refractory disease eventually emerges (Feldman and Feldman 2001; Shelley, 
Kumar et al. 2009). Currently, different recognized treatment options are available in case of 
local failure after radiation therapy such as radical prostatectomy, cryotherapy, high-intensity 
focused ultrasound (HIFU), chemotherapy (docetaxel), T cell Immunotherapy (Sipuleucel-T), 
and brachytherapy (Boukaram and Hannoun-Levi 2010; Kantoff, Higano et al. 2010). 
 
1.2.3 Cancer immunity 
Immunity has two main distinct effects on cancer. On one side, immunity prevents against 
the development of nascent tumors, defined as cancer immunosurveillance. In fact, 
compelling experimental studies in mouse models of cancer together with clinical data from 
human patients have uncovered cancer immunosurveillance functions as an effective 
extrinsic tumor suppressor mechanism (Smyth, Dunn et al. 2006). On the other side, 
immunity sculpts the intrinsic nature of developing tumors through the immunological 
pressure afforded by cancer immunosurveillance. This combination of host-protective and 
tumor-sculpting functions of the immune system throughout tumor development is termed 
cancer immunoediting (Dunn, Old et al. 2004). Cancer immunoediting refers to a dynamic 
process comprising of three phases: elimination, equilibrium, and escape (Dunn, Old et al. 
2004). Elimination consists of the classical concept of cancer immunosurveillance, where 
pre-malignant and early-stage malignant cells are directly or indirectly removed by immune 
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cells. Equilibrium is the period of immune-mediated latency after incomplete tumor 
destruction, and escape refers to the final outgrowth of tumors that have overcome 
immunological pressure. When the immune system ultimately fails to eliminate all 
transformed cells, tumors with reduced immunogenicity emerge capable of escaping 
immune destruction and, in some circumstances, harness or alter ensuing inflammatory 
reactions to their own benefit (Figure 1).  
 
 
Figure 1. Tumor-associated immune 
suppression. Several regulatory mechanisms 
limit the activity of tumor-reactive cytotoxic T 
lymphocytes (CTLs). Immune regulation can be 
intrinsic to CTLs through the unbalanced 
activation of costimulatory and inhibitory 
receptors. Tumor cells can produce immune-
suppressive factors, such as TGF-b, IL-6, IL- 
10, and VEGF, sometimes as a result of 
activated oncogenes, such as STAT3. 
Activation of STAT3 in tumor-infiltrating 
immune cells further suppresses their activity. 
Tissue remodeling and hypoxia induce the 
release of immune-suppressive factors such as 
adenosine, TGF-b, IL-10, and VEGF. Finally, 
tumors are often infiltrated with a broad range 
of regulatory cells such as T-regulatory cells 
(Tregs), type II NKT cells, myeloid-derived 
suppressor cells (MSC), tumor-associated 
macrophages (TAM), and tolerogenic DCs that 
produce a broad range of immune-suppressive 
factors, such as TGF-b, IL-6, IL-10, IL-13, IL-
23, prostaglandin-E2 (PGE2), IDO, and 
arginase I (Arg). TGF-b, transforming growth 
factor-b; IL-6, interleukin-6; VEGF, vascular 
endothelial growth factor; STAT3, signal 
transducer and activator of transcription 3; 
DCs, dendritic cells; IDO, indoleamine 2–3 
dioxygenase; NKT, natural killer T cells. 
(Adapted from (Stagg, Johnstone et al. 2007)).  
 
 
Given the now well-established importance of the immune system at controlling and shaping 
developing tumors (Smyth, Dunn et al. 2006; Zitvogel, Tesniere et al. 2006; Swann and 
Smyth 2007), more effective cancer therapies might be developed by understanding how 
tumors escape the immune system and more importantly, how to increase the 
immunogenicity of tumors.  
 
1.2.3.1 T regulatory cells 
In recent years, several populations of specialized regulatory cells have emerged as potent 
regulators of immune responses, including a number of T-cell subsets. One of the main 
mechanisms that the tumors use to escape anti-tumor immunity is through regulatory T cells 
(T-regs). T-regs fall into two main categories: those that are continuously produced by the 
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thymus and dependent on the expression of forkhead box p3 (Foxp3), such as CD4+ CD25+ 
Tregs, and those that arise as a result of peripheral encounters, such as IL-10-producing, 
Foxp3-negative Tr1 cells, and TGF-β- producing T helper type-3 (Th3) cells (Stagg, 
Johnstone et al. 2007). T-regs are activated in an antigen-specific manner but are generally 
believed to suppress T cells in an antigen-non-specific manner. Although the precise 
mechanisms of action of T-regs are not entirely clear, it has been suggested that T-reg-
mediated suppression is regulated by, among other molecules, CTLA-4 (Miyara and 
Sakaguchi 2007). Therefore, CTLA-4 is of important interest as a molecular target to 
breakdown the tumor immune tolerance.  
In addition to T-regs, T cells expressing both TCR and NK-cell receptors have also been 
shown to possess regulatory properties (Kronenberg 2005). CD1d-restricted NKT cells 
include two subsets: invariant type I NKT cells and non-invariant type II NKT cells. Whereas 
activation of type I NKT cells has potent immune stimulatory effects, type II NKT cells were 
shown to be sufficient to suppress tumor immunosurveillance (Terabe, Swann et al. 2005). 
Regulatory NKT cells can produce IL-13, which in turn can activate myeloid-derived Gr1high 
Mac1+ suppressor cells to produce TGF-β (Terabe, Matsui et al. 2003).  
 
1.2.3.2 A specific monoclonal antibody for the negative costimulatory receptor 
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152) 
Regulatory pathways that determine the immune response to cancer are becoming 
increasingly well characterized. One of these pathways involves the negative costimulatory 
receptor cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152). CTLA-4 is an 
activation-induced Type I transmembrane protein of the Ig superfamily which is expressed 
by T lymphocytes as a covalent homodimer  andfunctions as an inhibitory receptor for the 
costimulatory molecules B7.1 (CD80) and B7.2 (CD86) (Ribas, Hanson et al. 2007) (Figure 
2). CTLA-4 blockade with mAbs results in increased interleukin-2 (IL-2) and interferon-
gamma (IFN-γ) production by lymphocytes, and increased expression of major 
histocompatibility complex (MHC) class I molecules (Lee, Chuang et al. 1998; Paradis, Floyd 
et al. 2001). The preclinical antitumor efficacy of antagonistic antibodies to CTLA-4 has been 
previously shown in several tumor models, including decreased relapses when given as 
adjuvant immunotherapy in a model of metastatic PC (Leach, Krummel et al. 1996; Kwon, 
Foster et al. 1999). Currently, two fully human monoclonal antibodies (mAbs) with CTLA-4 
antagonistic activity are in clinical testing; ipilimumab (IgG1 isotype) (formerly MDX-010; 
developed by Medarex Inc.,Bloomsburg, NJ, and codeveloped with Bristol-Myers Squibb, 
Princeton, NJ) and tremelimumab (IgG2) (formerly CP-675,206; developed by Pfizer 
Pharmaceuticals Inc., NY). Several previous studies have accessed the biologic and clinical 
activity of ipilimumab and tremelimumab in patients with melanoma and other cancer types 
(Ribas, Hanson et al. 2007; Hodi, O'Day et al. 2010; Kirkwood, Lorigan et al. 2010). 
However, these therapeutic agents also have the potential to create long-lasting severe 
immune-related adverse events (irAEs) and even death   as a result of the disruption of T 
cell homeostasis or the breaking of tolerance to self antigens (Maker, Phan et al. 2005; Hodi, 
O'Day et al. 2010). A recent phase III clinical trial with ipilimumab in combination with 
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glycoprotein 100 (gp100) revealed that anti-CTLA4 alone had a median overall survival of 
10.1 months, similar to the combination group (Hodi, O'Day et al. 2010). However, grade 3 
or 4 immune-related adverse events occurred in 10 to 15% of patients treated with 
ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study 





Figure 2. CTLA-4 expressing cells and their respective interactions. All members of the 
immunoglobulin superfamily that act as inhibitory checkpoints are potential targets for manipulation in 
immunotherapies. CD28, CTLA-4, B7-1, and B7-2 are centrally important for the initial activation of 
naïve T cells of the clonal composition of the responding repertoire following migration of activated 
dendritic cells to lymphoid activation organs. As activated effectors traffic back into peripheral tissues, 
they come under the influence of PD-1–PDL-1–and PD-1–PDL-2–mediated signaling, as a result of 
interactions with both tissue macrophages and ligands expressed on malignant cells. B7-H3 and B7x 
might act as the final arbiters of the fate of T-cell effector interactions with nonlymphoid target tissues, 
and might protect tumor cells that express them from cytotoxic T-cell–mediated killing. The potential 
for crosstalk between T-cell populations via many of these pathways is complex, particularly because 
activated cells can upregulate receptors and/or ligands that can potentially signal bidirectionally. 
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Blockade of BTLA might remove inhibitory restraints imposed by HVEM-expressing cells, but effects 
on T-cell–T-cell interactions mediated by blockade of CTLA-4, PD-1 or PDL-1, or B7-H3 are also 
possible. Regulatory T cells provide an additional therapeutic target. Their mode of function in vivo is 
not entirely clear. Experimental evidence points to important roles for inhibitory cytokines, membrane 
bound TGF-β, and granzyme. The role of CTLA-4 remains controversial, but could be mediated via 
outside-in signaling through the B7 ligands.  
Abbreviations: BTLA, B- and T-lymphocyte attenuator; CTLA-4, cytotoxic T-lymphocyte antigen 4; 
HVEM, herpes virus entry mediator; IDO, indoleamine 2,3-digoxygenase; IL-2, interleukin-2; LIGHT, 
lymphtoxins, inducible, competes with herpes simplex virus glycoproteins D for HVEM, expressed by 
T cells; PD, programmed death; PDL, programmed death ligand; TGF-β, transforming growth factor β. 
Adapted from (Peggs, Quezada et al. 2006)  
 
 
Based on several in vitro studies, Ribas and colleagues (Ribas, Hanson et al. 2007) have 
proposed several potential mechanisms of antitumor responses mediated by anti-CTLA-4 
blocking antibodies (Abs). (A): Anti–CTLA-4 Abs can block the negative signaling derived 
from the activation-induced CTLA-4 molecule on the surface of activated T cells triggered by 
B7 costimulatory molecules on dendritic cells (DCs). (B): A subset of T regulatory cells that 
constitutively express CTLA-4 may provide reverse signaling by binding to B7 molecules on 
DCs, which can upregulate indoleamine 2,3-dioxygenase and thereby tolerize T cells in the 
microenvironment. (C): CTLA-4–expressing T cells may also bind directly to activated T 
cells, because B7 costimulatory molecules are expressed on the surface of activated human 
T cells. CTLA-4–blocking Abs would interfere with this negative signaling and result in the 
local expansion of tumor antigen-specific T cells. (D): CTLA-4 can be expressed on the 
surface of tumor cells. CTLA-4–blocking Abs may induce direct killing of tumor cells by 
triggering apoptosis or Ab-dependent cellular cytotoxicity. (E): Tumor-expressed CTLA-4 
may trigger increased indoleamine 2,3-dioxygenase in tumor-infiltrating DCs, and CTLA-4–
specific monoclonal Abs would also block this effect (Ribas, Hanson et al. 2007). However, 
the mechanism or mechanisms of action that mediate the increased anti-tumor effect in 
cancer patients is still not fully understood. 
1.3 Cancer Gene Therapy 
The ability of viruses to kill cancer cells has been known for more than a century (Kelly and 
Russell 2007). Their antitumor potency is obtained by several mechanisms, including direct 
lysis, apoptosis, expression of toxic proteins, autophagy and shut-down of protein synthesis, 
as well as the induction of anti-tumoral immunity. Even though clinical trials of several 
naturally-occurring oncolytic viruses date back to the 1950s, it was only in 1991 that a 
herpes simplex virus-1 (HSV-1) with deletion of its thymidine kinase UL23 gene became the 
first genetically-engineered, replication-selective oncolytic virus to be tested in the laboratory 
(Martuza, Malick et al. 1991). In 2005, an adenovirus (Ad) with E1B 55K and E3B genes 
deletion (H101(Oncorine); Shanghai Sunway Biotech, Shanghai, China) was approved in 
China as the world’s first oncolytic virus for HNC in combination with chemotherapy (Garber 
2006). Besides oncolytic virotherapy (OV) other cancer gene therapy strategies have been 
explored, mainly gene replacement therapies or expression of toxic proteins. However, 
promising laboratory results have not always been translated to improved clinical outcomes, 
and this appears to be determined by the complex interactions between the tumor and its 
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microenvironment, the virus, and the host immunity (Wong, Lemoine et al. 2010). Therefore, 
there is the need to develop more potent antitumor vectors as well as more effective 
therapeutic strategies.  
 
1.3.1 Oncolytic viruses 
Oncolytic viruses are viruses that are able to replicate specifically in and destroy tumor cells, 
and this property is either inherent or genetically-engineered. After replication, cancer cells 
are lysed and virus progeny is released to infect neighboring cancer cells. In principle, 
infection and replication can continue until all tumor cells are eliminated including distant 
metastasis (Qiao, Kottke et al. 2008). Several DNA and RNA viruses have been studied for 
their ability to replicate and lyse tumor cells such as adenoviruses, herpes viruses and pox 
viruses, (Vähä-Koskela, Heikkilä et al. 2007), however, not all were further developed for 
OV. Tumor-selective viruses can specifically target cancer by exploiting the very same 
cellular aberrations that occur in these cells, such as surface attachment receptors, activated 
Ras and Akt; and defective Rb/p16 and interferon (IFN) pathways (Sherr 1996; Wong, 
Lemoine et al. 2010).  
 
1.3.1.1 Adenoviruses 
Adenoviruses (Ad) were isolated in 1953 from human adenoid tissue samples in culture 
undergoing “spontaneous” regression, and were dubbed adenoidal–pharyngeal–conjunctival 
viruses based on their capacity to induce disease symptoms in experimentally infected 
humans (Rowe, Huebner et al. 1953). Since then adenoviruses have become the most 
widely used and most extensively studied viruses for gene delivery/therapy purposes. 
Oncolytic adenoviruses were the first and so far the only approved oncolytic viruses in 
combination with chemotherapy for the treatment of refractory HNC (Garber 2006).  
Several characteristics made possible that Ad was the first OV approved virus for treatment 
of cancer patients (Garber 2006). Ads have a natural lytic replication cycle and they are able 
to infect cells regardless of cell cycling status (Hemmi, Geertsen et al. 1998). Also, Ad 
production is efficient and stable particles are produced in high titers. The Ad genome is 
easily manipulated, being able to accommodate up to 105% of the wild type’s 36 kb genome, 
and there are several genome manipulating tools available to facilitate this process. In 
consequence, therapeutic transgenes can be easily incorporated into the viral genome in 
order to further improve the viral anti-tumor efficacy. In addition, the adenoviral genome 
stays episomal and thus mutational risk of infected cells is low. Finally, Ads have been 
extensively used in vaccination programs and the possible side effects are well known and 
easily resolved in normal conditions. 
 
1.3.1.1.1 Adenoviral general virology 
Adenoviruses are nonenveloped, icosahedral particles of approximately 90 nm in diameter 
containing linear, double-stranded DNA, and projecting fibers from the vertices of the 
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icosahedrons (Figure 3). As in many other nonenveloped viruses, Ad virions are mainly 
constituted of proteins and DNA, and some carbohydrates can also be found but not lipids 
(Russell 2000). The protein fraction is the main Ad constituent and it is formed by three 
major proteins (hexon (II), penton base (III), knobbed fiber (IV)) and five minor proteins (VI, 
VIII, XI, IIIa and IVa2) (Fig. 3). The virus’s genomic DNA is covalently bounded to a terminal 
protein (TP) in the 5’ termini containing inverted terminal repeats (ITRs) (Rekosh, Russell et 
al. 1977). In addition, the viral DNA is also associated with protein VII and the small peptide 
mu (Anderson, Young et al. 1989). Protein V is packaged with this DNA-protein complex and 
seems to provide a structural link to the capsid together with protein VI (Matthews and 
Russell 1995). Lastly, the protein fraction also contains a protease necessary for processing 
















Figure 3. Adenovirus structure; adapted from (Russell 2000). 
 
Besides respiratory diseases (Rowe, Huebner et al. 1953), Ads cause epidemic 
conjunctivitis (Jawetz 1959) and have been associated with a variety of additional clinical 
syndromes, especially infantile gastroenteritis (Mautner, Steinthorsdottir et al. 1995). In 
immune-competent patients, wild type Ads usually cause a mild, self-limiting acute infection. 
While in neonates and immune-suppressed patients, wild type Ads can cause severe 
infections (Krilov 2005).  
Currently, more than 100 members of the Ad group that infect a broad range of vertebrate 
hosts have been isolated. The Adenoviridae family is divided mainly in 4 clades: 
Mastadenovirus, Aviadenovirus, Atadenovirus and Siadenovirus; nomenclature is based on 
the vertebrate host origin (Davison, Benko et al. 2003). Bioinformatics analysis has proposed 
a fifth new clade (Davison, Benko et al. 2003). Fifty-one human Ad serotypes have been 
distinguished on the basis of their resistance to neutralization by antisera to other known 
human Ad (De Jong, Wermenbol et al. 1999). The various serotypes are classified into six 
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(A-F) subgroups (species) based on their ability to agglutinate red blood cells (Rosen 1960). 
For example, Ad serotype 3 belongs to the subgroup B and the Ad serotype 5 belongs to the 
subgroup C. 
The human Ad replication cycle has been mainly studied in Ad2 and Ad5 serotypes as 
models and so far it has been found to be equivalent to the other serotypes. The viral 
replication cycle is divided by convention into two phases that are separated by the onset of 
viral DNA replication. The early phase starts with the viral interaction with the host cell and it 
further includes adsorption, penetration, movement of partially uncoated virus particles to a 
nuclear pore complex (NPC), transport of viral DNA through the NPC into the nucleus and 
finally expression of an early set of genes. Early viral gene products mediate further viral 
gene expression and DNA replication, induced cell cycle progression, block apoptosis, and 
antagonize a variety of host antiviral measures. The late phase of the cycle begins with 
expression of late viral genes and assembly of progeny virions. Early transcription cassettes 
are termed E1-E4 and late transcription cassettes are divided into L1-L5 (Berk 2006).  
The initial viral interaction with the host cell is mediated by the knob fiber and the respective 
receptor on the cell surface. In vitro, the main receptor for the Ad subgroups A and C-F is the 
coxsackie-adenovirus-receptor (CAR) (Roelvink, Lizonova et al. 1998). However, for the 
other subgroups or in vivo more complex interactions might occur. On the consequence of 
the primary interaction a secondary interaction involving the cellular αvβ integrins and the 
viral penton base arginine-glycine-aspartic acid (RGD) is established. Once the secondary 
binding is established endocytosis mediated by clathrin coated pits occurs (Berk 2006). The 
newly formed endosome then migrates towards nucleus. During this migration the 
endosomal pH is acidified, resulting in the partial degradation of the viral capsid. When the 
endosome reaches the nuclear membrane the now partially degraded virion binds to the 
nuclear pore and injects the viral DNA into the nucleus (Berk 2006). 
The early E1 gene products are divided into E1A and E1B (E1B55K) proteins and they are 
expressed promptly upon adenovirus entry into a cell. Normally, the products of these genes 
act together to force the host cell to enter S phase, a prerequisite for the rest of the viral 
replication process. Deletion of E1A will render the virus susceptible to the anti-viral 
mechanisms of the retinoblastoma (Rb) protein, specifically by blocking the G1 to S 
transition. Deletion of E1B, on the other hand, allows p53 to induce apoptosis in infected 
cells, aborting replication and spread of the virus. In addition, the protein encoded in E4 
(E4orf6) alone or in complex with E1B-55k inhibits p53 mediated apoptosis (Berk 2006). The 
E2 gene products provide the machinery for virus DNA replication (Hay, Freeman et al. 
1995). E3 genes encode for several proteins to overcome the host defense mechanisms 
(Russell 2000). The E3 gp19K is localized in the ER membrane and binds the MHC class I 
heavy chain preventing transport to the cell surface, where it would activate cytotoxic T-
lymphocytes (Bennett, Bennink et al. 1999). Another important viral protein for this study is 
the E4orf3 encoded in E4, this protein as well as the E1B-55K/E4orf6 complex interact with 
the MRN complex inhibiting the cellular DNA damage response (Berk 2006). In HeLa cells 
the early phase lasts for 5 to 6 hours. The late genes L1-L5 result in the production of the 
viral structural components and the encapsidation and maturation of the particles in the 
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nucleus (Russell 2000). The complete viral cycle is complete after 24 to 36 hours in HeLa 
cells. 
1.3.1.1.2 Adenoviruses as gene transfer vehicles 
The presently available recombinant tools together with an easily modified and well studied 
genome made Ads the most used tools for gene transfer in scientific research as well as in 
gene therapy (Russell 2000). Conventionally, the term gene therapy is used to indicate gene 
delivery by insertion of nucleic acids into cells of an individual to treat a disease. The 
therapeutic transgene can supplement a defective gene (e.g. a tumor suppressor gene for 
the treatment of cancer or delivery of a functional gene into the target tissue in monogenic 
diseases), or encode RNA or protein with a therapeutic function. 
In the past few years several modifications have been performed in order to transform 
adenoviruses to be more effective, to be able to include more foreign genetic material in their 
genomes and to be less immunogenic. The initial viruses, also called first generation, were 
engineered by replacing the E1 region by the gene of interest. This first generation is the 
most widely used tool in basic research to achieve transient gene expression and several 
trials have also been performed based on this approach (Russell 2000). In order to create 
less immunogenic vectors and with a bigger capacity harbour genes of interest, a second 
generation was created by deleting the E1 and E3 regions in addition to the E2 or E4 
regions (Shen 2006). Finally, a third generation called gutless or helper-dependent virus was 
created by deleting basically all the viral genes with exceptions of the ITRs and the 
packaging signal. Of the engineered Ads for gene transfer, helper dependent viruses are the 
least immunogenic and with the biggest capacity for foreign genetic material (Shen 2006). 
 
1.3.1.1.3 Transductional targeting  
Ad5 is the most used serotype in adenoviral gene therapy and similarly to other serotypes, 
CAR is, in vitro, the primary receptor (Roelvink, Lizonova et al. 1998). Consequently, 
efficiency of gene transfer is conditioned by the CAR expression levels. CAR is highly 
expressed in epithelial cells as well as in heart, pancreas, the central and peripheral nervous 
system, prostate, testis, lung, liver and intestine; but little or no CAR is expressed on 
lymphocytes or adult muscle (Meier and Greber 2004). This makes Ad5 a broad tool for 
gene transfer. However, cancer progression is correlated with a decrease in CAR expression 
levels on tumor cells (Anders, Christian et al. 2003). Thus, it would be advantageous to 
transductionally retarget adenovirus to non-CAR receptors for increased tumor transduction 
and/or reduced infection of non-target tissues (Kanerva, Zinn et al. 2003; Bauerschmitz, 
Guse et al. 2006). Several strategies can be used to achieve a none-CAR dependent 
transduction, mainly divided in adapter-molecule based retargeting, and genetic 
manipulation of the viral capsid. 
The adapter-molecule based retargeting consists of a bi-specific ligand that bridges a 
connection between a receptor in the cell surface and the Ad. Several strategies have been 
tested as, for example, bi-specific antibodies (Korn, Muller et al. 2004), cell-selective ligands 
such as folate (Douglas, Rogers et al. 1996) and chemical conjugates (Reynolds, Zinn et al. 
‐ 20 ‐ 
2000). However, by using a two component system the risk of unexpected side effects is 
increased and the production of such bi-specific ligands is often complex, ending up with 
impure mixes of ligands that increases even further the risk of side effects. 
To the present day, transductional retargeting by genetic manipulation of the viral capsid has 
been obtained by ligand incorporation into the fiber, replacing fiber regions with a ligand, or 
by serotype fiber knob switching (Bauerschmitz, Barker et al. 2002; Glasgow, Everts et al. 
2006). Several ligands have been studied as well as different localization modifications in the 
fiber. The C-terminus and the HI-loop within the fiber revealed promising regions for ligand 
insertion. A polylysine tail constituted of 7 lysine residuesthat retargets the virus to cell 
surface heparin sulfate proteoglycans (HSPGs), has been successfully inserted into the fiber 
C-terminus with increased transduction of cancer cells (Kangasniemi, Kiviluoto et al. 2006; 
Ranki, Kanerva et al. 2007). Enhanced infectivity of tumor cells was also obtained by 
inserting the RGD motif targeting αvβ integrins into the HI-loop (Kanerva, Wang et al. 2002; 
Kangasniemi, Kiviluoto et al. 2006) as well as into the hexon monomer protein (Vigne, 
Mahfouz et al. 1999). Furthermore, combination of pK7 in the C-terminus and RGD motif in 
the HI-loop revealed increased transduction of CAR deficient cells (Wu, Seki et al. 2002). 
Transductional retargeting can also be obtained by replacing the knob or other fiber regions 
with a ligand. For example, by replacing the penton base RGD motif responsible for the 
secondary viral interaction with receptor specific motifs, Ad can be targeted to different 
cancer tissues (Wickham, Carrion et al. 1995). Finally, serotype fiber knob switching has 
revealed promising results by replacing the knob of the Ad5 by another serotype knob e.g. 
serotype 3 knob retargeting to the Ad3 receptor (Kanerva, Mikheeva et al. 2002). 
 
1.3.1.1.4 Transcriptional targeting 
Since the first generation Ad, the anti-tumor efficiency of adenoviral cancer gene therapy has 
been improved by taking advantage of viral replication and by arming the vectors with 
therapeutic transgenes. However, despite these improvements there was also the need to 
decrease possible off-target side effects. For this purpose, transcriptional targeting to tumor 
cells has been explored where viral genes or other transgenes in the viral genome can only 
be transcribed in malignant cells and not in normal cells. Transcriptional targeting can be 
obtained by placing viral genes fundamental for viral replication under the control of tissue-
specific promoters (TSPs) that are activated in tumor cells but not usually in normal cells. 
Consequently, the early viral genes, especially the E1A gene has been placed under the 
control of several promoters, such as E2F (Tsukuda, Wiewrodt et al. 2002), cyclooxygenase-
2 (Cox-2) (Bauerschmitz, Ranki et al. 2008) and human telomerase (hTERT) (Hashimoto, 
Watanabe et al. 2008) with increased tumor retargeting.  
More recently, gene silencing by RNA interference technology has been utilized to confer 
tumor selectivity. MicroRNAs (miRNAs) or small interfering RNAs (siRNAs) regulate gene 
expression post-transcriptionally by translation block or cleavage of specific, complementary 
mRNA via the RNA-induced silencing complex (RISC). By inserting a complementary 
sequence next to a critical viral gene, it is possible to restrict virus replication to tumor but 
not normal cells that express high levels of the corresponding miRNA. This has been 
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demonstrated by several groups (Kelly, Hadac et al. 2008; Ylosmaki, Hakkarainen et al. 
2008).  
 
1.3.1.1.5 Transcomplementation targeting 
Several clinical trials have revealed Ads as a safe and promising therapy for cancer (Harvey, 
Maroni et al. 2002; Peng 2005; Pan, Zhang et al. 2008; Ylä-Herttuala 2008). However, the 
main conclusion from most cancer trials is that tumor transduction and tumor penetration 
have been too low for a significant therapeutic antitumor effect (Harvey, Maroni et al. 2002; 
Pan, Zhang et al. 2008; Ylä-Herttuala 2008). Therefore, oncolytic viruses have been 
explored for enhanced tumor transduction and amplification of effect (Kanerva and 
Hemminki 2004). As a result, transductional and transcriptional targeting have been explored 
to target the viral replication and in this way abrogate the viral replication in normal healthy 
tissue. In addition, viral replication can be restricted to tumor cells by deleting adenoviral 
genes that are necessary for viral replication in normal cells but not in tumor cells. In fact, 
adenoviral infection induces several signaling pathways that are also abnormally induced in 
tumor cells (such as cell cycle deregulation and inhibition of apoptosis) (Yew and Berk 1992; 
Lukas, Muller et al. 1994; Han, Modha et al. 1998).  
The first engineered, oncolytic Ad to enter clinical trials for cancers including those of the 
HNC was dl1520 (ONYX-015; Onyx Pharmaceuticals, California, USA) (Heise, Sampson-
Johannes et al. 1997; Khuri, Nemunaitis et al. 2000; You, Yang et al. 2000; Kirn 2001; Reid, 
Galanis et al. 2002; Hecht, Bedford et al. 2003). This virus is an oncolytic Ad2/Ad5 hybrid 
with deletion of its E1B 55K and it has shown safety (Nemunaitis, Cunningham et al. 
2001).Furthermore, the virus H101 was the first oncolytic Ad to be approved for cancer 
treatment. H101 is similar to ONYX-015 but with an additional deletion of the E3B genes 
deletion. However, the specificity of E1B-deletion mutants to p53-negative cells is not 
absolute, but instead it is the capacity of cells to compensate for late mRNA transport 
(another function of 55k) which determines selectivity (O'Shea, Johnson et al. 2004). Also, 
the lack of E1B can be compensated by drugs or hyperthermia, enhancing the replication of 
E1B-deleted adenoviruses (Vähä-Koskela, Heikkilä et al. 2007). In addition, durable 
objective responses with this virus as a single agent have been limited and this could be 
partly due to the loss of other essential functions of the E1B 55K and E3B genes that 
resulted in significantly lower efficiency than the wild type virus in lysing cells in G1 status 
(Harada and Berk 1999). Thus, there is a need to improve these viruses by identifying 
mutations that result in tumor selectivity but not those that result in attenuated virus 
replication and oncolysis.  
The adenoviral E1A is the first gene to be transcribed after virus entry into the host cell 
(Frisch and Mymryk 2002). E1A normally interacts with the retinoblastoma protein (pRb) 
thereby releasing E2F and thus pushing quiescent cells into S phase to allow virus 
replication (Figure 4). E1A-deletion mutants, such as Δ24 (dl922–947), have shown superior 
oncolytic efficacy compared to E1B mutants both in vitro and in vivo (Fueyo, Gomez-
Manzano et al. 2000; Heise, Hermiston et al. 2000). The approach is based on the fact that 
most advanced human tumors are deficient in the pRb/p16 pathway (Sherr 1996; Hernando, 
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Nahle et al. 2004). Therefore, by deleting the Δ24 bp (dl922–947) of E1A, the interaction 
with pRb is lost and the virus can not replicate in normal cells. However, the abnormally 
activated pRb/p16 pathway in tumors cells which have already free E2F that 













Figure 4. Early adenoviral proteins lead to loss of cell cycle control and cell arrest. The 
retinoblastoma protein family (pRb) regulates the G1 to S-phase cell cycle checkpoint. pRb prevents 
progression of the cell cycle from G1 to S phase by binding to and repressing transcription factor E2F, 
which normally induces expression of genes needed for DNA synthesis. When pRb is phosphorylated 
by cyclin-dependent kinase 4 (CDK4), it is unable to bind to and repress E2F. Another protein 
relevant for the cell cycle control is the tumor suppressor transcription factor p53, which is 
upregulated and activated upon stress signals like DNA damage or viral infection. p53 can activate 
transcription of genes coding for proteins that either induce apoptosis (for example Bax) or cell cycle 
arrest (for example p21). p21 is able to inactivate CDKs, thereby inhibiting progression through the 
cell cycle. The activity of p53 is blocked by Mdm2, which inactivates p53 through binding and 
mediating degradation. The effect of Mdm2 can be inhibited by p14ARF, a tumor suppressor protein 
that is upregulated by stress signals and mitogenic signals, like E2F. As E2F activity is blocked by 
pRb, inactivation of pRb leads to activation of p53 and functions as a safety mechanism during 
progression through the cell cycle. However, targeted deletions in E1B-55 kD or E1A result in mutant 
proteins that are unable to bind p53 or pRb, respectively. Therefore, modified viruses replicate only in 




The strategies of transductional, transcriptional and conditionally replicating targeting are not 
independent of each other. Consequently, increased tumor targeting and decreased 
possible side effects can be accomplished by combining the three approaches. 
Bauerschmitz and colleagues showed that a triple targeted virus exhibits increased tumor 
cell selectivity while retaining oncolytic potency (Bauerschmitz, Guse et al. 2006). 
 
1.3.2 Arming approaches for enhanced antitumor efficacy 
Advanced tumor masses are very complex and heterogeneous having several barriers that 
impair an efficient oncolytic viral spread (Hay 2005; Cheng, Sauthoff et al. 2007). Heretofore, 
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oncolytic viruses’ anti-tumor efficacy can be further improved by taking advantage of the 
unique viral efficiency of gene delivery and arm the viruses with anti-tumor transgenes. In 
comparison to first generation none replicative viruses, to couple the expression of anti-
tumor genes to virus replication promotes higher transgene expression as well as during 
longer periods (Hawkins, Johnson et al. 2001). The reason has been that transgene 
expression is not limited to a single cycle of replication as in the first generation viruses 
(Peng 2005). Furthermore, the oncolytic virus tumor targeting features permit high transgene 
expression levels locally to the tumor and therefore decreasing possible systemic side 
effects of the therapeutic proteins. Recently, arming oncolytic viruses with anti-cancer genes 
has been a major focus in cancer virotherapy, and transgenes exploited include tumor 
suppressor, pro-apoptotic, anti-angiogenic, “suicide”, and immunomodulatory genes.  
With the increased knowledge of tumor genetics a logic strategy would be to correct the 
deficient genes in the tumor cells. Therefore, tumor suppressor and pro-apoptotic 
transgenes such as p16INK4A (Ma, He et al. 2009) or p53 (Wang, Su et al. 2008) armed 
viruses were among the first to be tested. However, targeting a single gene is not enough to 
achieve a significant result with regard to the extreme complexity of mutations in the tumor 
cells and the difficulty in transducing sufficient amounts of cells (Stratton, Campbell et al. 
2009). For this reason it would be more advantageous to target signaling pathways instead 
of individual genes such as arming with transforming growth factor beta (TGF-β) (Hu, 
Robbins et al. 2009). 
Tumor increased vasculature is directly correlated with disease progression. Therefore, 
several anti-angiogenic molecules have been developed in order to reduce tumor 
vasculature and tumor progression. Recently, oncolytic viruses have been armed with a 
broad spectrum of anti-angiogenic factors such as endostatin/angiostatin (Su, Na et al. 2008; 
Fang, Pu et al. 2009; Tysome, Briat et al. 2009), interleukin-18 (IL-18) (Zheng, Pei et al. 
2009; Zheng, Pei et al. 2009), canstatin (He, Su et al. 2009), and trichostatin A (Liu, Castelo-
Branco et al. 2008), as well as arming viruses with genes that inhibit pro-angiogenic 
molecules such as IL-8 (Yoo, Kim et al. 2008) and vascular endothelial growth factor (VEGF) 
(Guse, Diaconu et al. 2009). In addition, oncolytic viruses coding for matrix 
metalloproteinases (MMPs) inhibitors have shown promising results in delaying tumor 
growth and angiogenesis (McNally, Rosenthal et al. 2009).  
Another strategy used for arming oncolytic viruses, gene-directed prodrug activation therapy 
(or suicide gene therapy), involves the delivery of a gene that would lead to the expression 
of an enzyme, followed by the administration of a prodrug that is activated selectively by this 
enzyme. The best known example is herpes simplex thymidine kinase (HSV-TK), where the 
non-toxic drug ganciclovir (GCV) is converted into triphosphorylated forms, blocking DNA 
synthesis and inducing cell death (Wong, Lemoine et al. 2010). In addition, the 
phosphorylated toxic metabolites can spread to non-infected cells creating a cytotoxic 
bystander effect. The efficiency of the approach has been tested in oncolytic Ad vectors 
(Raki, Hakkarainen et al. 2007). Alternative combinations include nitroreductase with the 
prodrug CB1954 (converted into an alkylating agent) (Braidwood, Dunn et al. 2009), and 
cytosine deaminase (CD) with 5-fluorocytosine, which is converted into the cytotoxic and 
radiosensitizing 5-fluorouracil (Chalikonda, Kivlen et al. 2008; Foloppe, Kintz et al. 2008).  
‐ 24 ‐ 
With the discovery of immunosurveillance and the importance of the immune system in the 
development of cancer, a plethora of immunomodulatory genes have been inserted into the 
genome of oncolytic viruses with the aim of stimulating effective anti-tumoral immune 
responses. Furthermore, viral mediated cell oncolysis has the potential to work as a tumor 
vaccine increasing the anti-tumor efficiency of immunodulatory molecules. Recent examples 
include the heat shock proteins (Li, Liu et al. 2009), chemokine (C-C motif) ligand 5 (CCL5) 
(Lapteva, Aldrich et al. 2009), IFN (Willmon, Saloura et al. 2009), granulocyte macrophage 
colony-stimulating factor (GM-CSF) (Chang, Zhao et al. 2009; Cerullo, Pesonen et al. 2010), 
IL-12 (Bortolanza, Bunuales et al. 2009), IL-18 (Zheng, Pei et al. 2009), and IL-24 (Luo, Xia 
et al. 2008). 
A possible problem of arming oncolytic viruses with anti-tumor transgenes is that the viral 
replication and spread can in theory be hindered by the transgenes. Nevertheless, the 
several studies so far have revealed that it is feasible and efficacious to arm oncolytic 
viruses with transgenes resulting in more potent anti-tumor vectors. Furthermore, side 
effects of the treatments are usually non-overlapping, which might facilitate increased 
efficacy without increasing toxicity. 
 
1.3.3 HNC clinical trials with oncolytic adenoviruses  
Over 1000 cancer gene therapy clinical trials have been done so far representing 64.5% of 
all clinical trials in gene therapy (source The Journal of Gene Medicine Clinical Trial site). 
The currently employed oncolytic adenoviruses in clinical trials are all based on human 
adenovirus serotype 5, although they employ different modes of tumor selectivity. The first 
oncolytic adenoviruses tested in clinical trials was ONYX-015 in 1996 (described in chapter 
1.3.1.1.5) and successfully established the clinical proof-of-concept of adenoviral gene 
therapy for HNC (Ganly, Kirn et al. 2000). Single agent efficacy has been relatively limited to 
about 14% of local tumor regression rates. Nevertheless, in a phase II clinical trial the anti-
tumor efficacy of the vector was improved when in combination with chemotherapy (Khuri, 
Nemunaitis et al. 2000). A promising Phase III clinical trial of ONYX-015 in combination with 
chemotherapy for HNSCC was started in 2003 but unfortunately due to funding problems 
was stopped.  
Another oncolytic Ad to undergo clinical testing and so far the only one to be approved in 
2005 for the treatment of HNC was H101 (described in chapter 1.3.1.1.5). H1O1 clinical 
testing started in the year 2000 in a phase I clinical trial for HNC in a dose-escalation 
manner similar to ONYX-015 (Yuan, Zhang et al. 2003). The highest given dose was 
intratumorally at 1.5x1012 VP and no dose limited toxicity (DLT) nor serious adverse events 
were seen. The phase II multicenter open-label clinical trial was performed from 2001 to 
2002 showing the safety of the virus (Xu, Yuan et al. 2003). Also, in this phase II clinical trial 
promising anti-tumor results were observed when in combination with chemotherapy (Xu, 
Yuan et al. 2003). In addition similar results as single agent in comparison to Onyx-015 were 
observed (Xu, Yuan et al. 2003). These findings prompted a multi-center, randomized and 
controlled phase III clinical trial from 2002 to 2004 (Xia, Chang et al. 2004). The clinical trial 
of H101 in combination with cisplatin and 5-FU showed an impressive response rate of 
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78.8% (41/52) compared to just 39.6% (21/53) of chemotherapy alone (Xia, Chang et al. 
2004). Other selected clinical trials with oncolytic Ads are listed in Table 1. 
In summary, clinical trials with oncolytic adenoviruses have been proven safe. However, to 
access antitumor efficacy further phase III randomized clinical trials are needed. 
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Abbreviations: 5-FU, 5-fluorouracil; ADP, adenoviral death protein; CD, cytosine deaminase; GCV, ganciclovir; 
HCC, hepatocellular carcinoma; MAP, mitomycin-.C-doxorubicin-cisplatin; i.ha, intrahepatic artery; i.t., intratumoral; 
i.v., intravenous; mitomycin-C-doxorubicin-cisplatin; PSA, prostate specific antigen; TK, tyrosine kinase; GMCSF, 
granulocyte-macrophage colony stimulating factor;  
*, clinicaltrials.gov NCT00583492 
 
‐ 27 ‐ 
2 AIMS OF THE STUDY 
 
This study was performed in order to develop and evaluate new adenovirus based treatment 
modalities for HNSCC and PC. Adenoviral gene therapy was utilized and new vectors were 
developed. The aims of this study were as follows: 
 
 
1. To investigate the anti-tumor efficiency of the combination of oncolytic 
adenoviruses with cetuximab, radiotherapy and/or chemotherapy in HNSCC. (I) 
 
2. To study the mechanism contributing to viral radiosensitization of tumors in 
vivo. (II) 
 
3. To generate and evaluate a transductionally and transcomplementary targeted 
oncolytic adenovirus armed with a prodrug converting suicide transgene to 
enhance specificity and increase antitumor effect due to the bystander effect 
prompted by the pro-drug enzymatic conversion. (III) 
 
4. To generate and evaluate a transductionally and transcomplementary targeted 
oncolytic adenovirus armed with a fully human monoclonal antibody specific for 
CTLA-4 to enhance specificity and increase antitumor effect due to immune 
response prompted by the immunomodulating molecule. (IV) 
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3 MATERIALS AND METHODS 
Detailed description of the used methodology can be found in the original publications. 
 
3.1 Cell lines; low passage tumor cell cultures (I-IV) 
Characteristics of the cell lines used in the studies are described in Table 2 
 
Table 2. List of human cell lines used in the studies 
 
Cell line name Description Used in
293 Transformed embryonic kidney cells I-IV 
911 Transformed embryonic retinoblasts III 
A549 Lung adenocarcinoma I-IV 
DU-145 Prostate carcinoma II 
Jurkat (E6-1) Leukemic T cell lymphoblast IV 
M4A4-LM3 Breast carcinoma II 
PC-3MM2 Prostate carcinoma II, IV 
SKOV3-ip1 Ovarian adenocarcinoma IV 
UT-SCC 8 Supraglottic larynx HNSCC low passage tumor cell cultures I-IV 
UT-SCC 9 Glottic larynx HNSCC low passage tumor cell cultures I 
UT-SCC 10 Mobile tongue HNSCC low passage tumor cell cultures I 
UT-SCC 29 Glottic larynx HNSCC low passage tumor cell cultures I, III 
 
Cell lines were subcultured according to the recommended conditions and not used with 
passage numbers above thirty. 
HNSCC low passage tumor cell cultures were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum (FCS) (PromoCell GmbH, 
Heidelberg, Germany), 1% nonessential amino acids (Gibco, Invitrogen, Carlsbad, CA, USA) 
2 mmol/L glutamine, 100 units/mL penicillin, and 100 Ag/mL streptomycin (all from Sigma, 
St. Louis, MO) (Erjala, Sundvall et al. 2006). 
 
3.2 Human specimens 
Peripheral blood mononuclear cells (PBMC) of healthy individuals and patients with 
advanced metastatic tumors refractory to conventional therapies were obtained with written 
informed consent. The study was completed according to Good Clinical Practice and the 
Declaration of Helsinki. This Advanced Therapy Access Program is approved by the 
Medicolegal Department of the Finnish Ministry of Social Affairs and Health and the Gene 
Technology Board, and is regulated by Finnish Medicines Agency Fimea. 
 
3.3 Adenoviruses 
Large scale production of replication deficient viruses and replication competent viruses 
were performed respectively in 293 and A549 cells and purified on double cesium chloride 
gradients. Presence of inserted genes and absence of wild-type virus was confirmed by PCR 
and sequencing. Virus particle (VP) concentrations were assessed by measuring 
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absorbance at 260nm and plaque forming unit (PFU) titers were assessed with standard 
TCID50 assay on 293 cells. 
 
3.3.1 Replication deficient adenoviruses 
The main features of the replication deficient adenoviruses used in the studies are described 
in Table 3. 
 
Table 3. List of replication deficient adenoviruses used in this study 
Virus name E1 * Fiber Used in Reference 
Ad5(GL) GFP + luciferase Wild type serotype 5 I, II (Wu, Seki et al. 2002) 




Ad5lucRGD Luciferase RGD motif in HI loop 
I (Dmitriev, 
Krasnykh et al. 
1998) 
Ad5.pK7(GL) GFP + Luciferase 7 lysine residues at COOH terminus 
I (Wu, Seki et 
al. 2002) 
Ad5.RGD.pK7(GL) GFP + Luciferase 
7 lysine residues at COOH 
terminus and RGD motif in 
HI loop 
I (Wu, Seki et 
al. 2002) 
Ad5/3-aCTLA4 anti-CTLA mAb 5/3 serotype chimerism IV Study IV 
Ad5/3-FCU1 FCU1 5/3 serotype chimerism III Study III 
Ad5/3luc1 Luciferase 5/3 serotype chimerism 
I, III, IV (Kanerva, 
Mikheeva et 
al. 2002) 
AdTG14800 FCU1 Wild type serotype 5 III (Erbs, Regulier et al. 2000) 
rAdE4orf3 E4orf3 + GFP Wild type serotype 5 
II (Araujo, 
Stracker et al. 
2005) 
rAdE1B55K E1B55K Wild type serotype 5 
II (Marcellus, 
Teodoro et al. 
1996) 




* The marker genes and transgenes in E1 are under control of the CMV promoter 
 
 
3.3.2 Replication competent adenoviruses 
The main features of the replication competent adenoviruses used in this study are 







Table 4. List of replication competent adenoviruses used in this study 
Virus name E1 E3 Fiber Used 
in 
Reference 
Ad300wt Wild type Wild type Wild type serotype 5 I, II ATCC1 
Ad5-Δ24E3 24 bp deletion2 Δgp19 
Wild type serotype 5 
 (Kanerva, Zinn 
et al. 2003) 
Ad5-Δ24RGD 24 bp deletion2 Wild type RGD motif in HI loop I (Suzuki, Fueyo et al. 2001) 
Ad5/3-Δ24 24 bp deletion2 Wild type 5/3 serotype chimerism I, III, IV (Kanerva, Zinn et al. 2003) 
Ad5/3-
Δ24aCTLA4 
24 bp deletion2 anti-CTLA 
mAb 5/3 serotype chimerism 
IV Study IV 
Ad5/3-Δ24FCU1 24 bp deletion2 FCU1 5/3 serotype chimerism III Study III 
Ad5.pK7-Δ24 24 bp deletion2 Wild type 7 lysine residues at 
COOH terminus 
I (Ranki, 
Kanerva et al. 
2007) 
1 virus purchased from American Type Culture Collection  
2 24 bps deleted in the constant region 2 (CR2) of the E1A gene 
 
3.3.3 Construction of Ad5/3-FCU1, Ad5/3-Δ24FCU1, Ad5/3-aCTLA4, Ad5/3-
Δ24aCTLA4  
For construction of Ad5/3-FCU1 and Ad5/3-aCTLA4, expression cassettes with either FCU1 
fusion gene (Erbs, Regulier et al. 2000) or the heavy and light chains of IgG2 type anti-
CTLA4 mAb were inserted into the multiple cloning site of pShuttle (Stratagene, La Jolla, 
CA, USA). Shuttle plasmids were recombined with pAdeasy-1 plasmid (Stratagene), which 
carries the whole adenovirus genome, and resulting rescue plasmids were transfected to 
293 cells to generate Ad5/3-FCU1 and Ad5/3-aCTLA4. For construction of oncolytic Ad5/3-
Δ24FCU1 and Ad5/3-Δ24aCTLA4, the gene for FCU1 fusion gene (Erbs, Regulier et al. 
2000) or the heavy and light chains of IgG2 type anti-CTLA4 mAb was cloned into pTHSN 
plasmid that contains the E3 region of the adenoviral genome replacing the 6.7K/gp19K 
genes (Kanerva et al., 2005). The resulting plasmid was recombined with pAdeasy-1.5/3-
Δ24, an adenovirus rescue plasmid containing the serotype 3 knob and a 24 bp deletion in 
E1A (Kanerva, Zinn et al. 2005), resulting in pAdeasy-1.5/3-Δ24-FCU1 or pAdeasy-1.5/3-
Δ24-aCTLA4, which were transfected to 911 or A549 cells for generation of Ad5/3-9HIF-






3.4 In vitro studies 
 
3.4.1 Marker gene transfer assays (I) 
Cell lines were seeded on day 1 at 25,000 cells per well on 24-well plates in 1 ml growth 
media (GM). On day 2, cells were infected with 40, 200, 1000 or 5000 VP/cell for 30 minutes 
in 2% GM on a shaker. Afterwards, cells were washed once with 1 ml PBS and 1 ml GM was 
added per well. After 24 hours the GM was removed, cells were lysed with 200 μl lysis buffer 
(Reporter Lysis Buffer, Promega, Madison, WI) and freeze-thawed once. 20 μl of these 
samples was mixed with 100 μl of luciferase assay reagent (Reporter Lysis Buffer, Promega, 
Madison, WI) and measured with Berthold Lumat LB9501. Standardization was 
accomplished by setting the values obtained with isogenic control virus with an unmodified 
serotype 5 capsid, which was given the value of 100%. 
 
3.4.2 Cytotoxicity assay (I-IV) 
Cells were seeded at a density of 1.5 x 104 cells/well for HNSCC cells or 1 x 104 cells/well for 
the other cell lines on 96-well plates and cultured overnight. Briefly, cells were either infected 
with variable concentrations of viruses or treated with agents, or treated with a combination 
of both. Detailed description of doses and schedules utilized in different studies can be found 
in the original publications. Cells were incubated at 37°C until almost complete cell killing 
was visually evident. Thereafter, cell viability was measured with the CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (MTS assay) (Promega, Madison, WI, USA). 
 
3.4.3 Radiotherapy (I, II) 
In vitro, cells were irradiated on cell culture plates through a 1 cm thick plastic phantom 
bottom and 1 cm thick layer of water in the phantom. Mice remained free in standard plastic 
cages that were placed in the middle of the radiation field. Irradiation was performed with a 
linear accelerator (model: Clinac 600 C/D, Varian Medical Systems, Palo Alto, USA) using a 
6 MV photon beam and dose rate 400 MU/min (≈4 GY/min).  
 
3.4.4 Western blot (II, III, IV) 
Cancer cells were seeded on 6-well plates and infected with viruses. Detailed description of 
doses and schedules utilized in different studies can be found in the original publications. 
Briefly, cell lysates, proteins or supernatants were run in SDS–polyacrylamide gel 
electrophoresis (PAGE) gel under reducing or native conditions and transferred to a 
nitrocellulose membranes. The membrane was incubated with primary antibody against the 
protein of interest, washed and incubated with secondary antibody coupled to horseradish 
peroxidase. Signal detection was done by enhanced chemiluminescence (GE Healthcare, 
Amersham, UK).  
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3.4.5 Immunofluorescence microscopy (I, II) 
Tumor cryosections or PC-3MM2 cells were fixed in 4% paraformaldehyde (room 
temperature), permeabilized and blocked at room temperature. Briefly, indirect 
immunofluorescent labeling was used (I, II) by incubating the slides with primary antibody, 
washed and incubated in the dark with secondary antibody. Also, direct immunofluorescent 
labeling technique was used (I) by incubating the slides with primary antibody conjugated 
with the APC, washed and tumor sections were post-fixed with 4% paraformaldehyde. In 
either indirect or direct immunofluorescent the slides were washed in PBS and mounted with 
Vectashield. Intensity ratios were calculated using Image J 1.39a (Wayne Rasband, National 
institutes of Health, USA) 
 
3.4.6 Clonogenic assay (II) 
On day 1, PC-3MM2 cells were seeded at 5x104cells/well into 24-well plates and infected on 
day 2 with the respective indicated viruses at 100 VP/cell. On day 3, plates were irradiated 
with 0 or 8 Gy and the cells were transferred to six-well plates at densities of 1000 cells/well. 
On day 13, the cells were fixed with 10% paraformaldehyde and stained with 1% crystal 
violet in 70% ethanol. Colony formation was counted under a microscope.  
 
3.4.7 Enzymatic assays by HPLC (III) 
On day 1, PANC-1 cells were seeded at 2 x 106 cells/well and on the following day infected 
with the respective viruses at an MOI of 25 VP/cell. Twenty four hours later, enzymatic 
activities were determined using HPLC separation as described in Erbs et al. (Erbs, Findeli 
et al. 2008).  
The CDase activity in tumors and plasma was determined using HPLC separation. Nude 
mice bearing s.c. HNSCC tumors infected with the respective viruses at an MOI of 3x108 
VP/day (days 0, 2 and 4) and treated intraperitoneally (i.p.) with 5-FC (250 mg/kg/day) or 
phosphate buffered saline (PBS). Plasma was separated by centrifugation from blood 
collected via tail vein in heparinized tubes, 1 hour post-5-FC i.p. injection. Tumors were 
homogenized using a Polytron homogenator. Tumor or plasma samples were quenched with 
1 ml of ethyl acetate/2-propanol/0.5 m acetic acid solution (84:15:1). The organic 
supernatant was reconstituted in 50 µl of water and analyzed by HPLC as described above. 
 
3.4.8 Immunostaining for apoptosis or human IgG (III-IV) 
Cryosections of 4–5μm thickness of frozen tumors embedded in Tissue Tek OCT. (Sakura, 
Torrance, CA, USA) were fixed in acetone for 10 min at -20◦C. Detailed description of doses 
and schedules utilized in different studies can be found in the original publications. Briefly, 
tissue sections were incubated with primary antibody against active caspase 3 or human 
IgG. Further, sections were incubated according to manufacturer’s instructions with LSAB2 
System-HRP kit (K0673, DakoCytomation, Carpinteria, CA, USA). Bound antibodies were 
‐ 33 ‐ 
visualized using 3,3’-diaminobenzidine (DAB,Sigma, St Louis, MO, USA). Lastly, sections 
were counterstained with hematoxylin and dehydrated in ethanol, clarified in xylene and 
sealed with Canada balsam. Representative pictures were captured at 20X or 40X 
magnification using an Leica DM LB microscope equipped with Olympus DP50 color 
camera. 
The immunohistochemistry images of tumor cryosections stained for apoptosis were 
analysed using Matlab from MathWorks (III). The color space of each image was simplified 
to the 10 most representative different colors by using K-means algorithm (Ilea and Whelan 
2006). The simplified colors were labeled as being red, blue or background. The resulting 
areas were filtered based on shape features to increase accuracy (Stanescu, Burdescu et al. 
2007). 
 
3.4.9 Quantitative real-time PCR (III) 
Total DNA was extracted from UT-SCC8 HNSCC low passage tumor cell cultures or tumors 
with QIAamp DNA mini kit (Qiagen, Valencia, CA, USA) and DNA concentration was 
measured by spectrophotometry. PCR amplification was based on primers and probe 
targeting of the E4 gene (Kanerva, Wang et al. 2002). Human beta-actin primers and probe 
were used as internal control and to normalize the number of viral DNA copies for the 
amount of genomic DNA (Alvarez-Lafuente, Garcia-Montojo et al. 2007). 
The real-time PCR conditions were as follows: 2X LightCycler480 Probes Master Mix 
(Roche, Mannheim, Germany), 500nM each forward and reverse primer, 150nM each probe 
and 5 µl extracted DNA. PCR reactions were carried out in a LightCycler (Roche, Mannheim, 
Germany) under the following cycling conditions: 10 min at 95°C, 50 cycles of 15 s at 95°C 
and 1 min at 60°C, and 10 min at 40°C. A regression standard curve was established using 
DNA extracted from serial dilutions of pAd5easy plasmid. Known amounts of human 
genomic DNA were used to generate a standard curve for the beta-actin gene. 
 
3.4.10 Biological activity of anti-CTLA4 measured by flow cytometry array of IL-
2 or INF-γ (IV) 
Cancer patients with advanced solid tumors or healthy donor PBMCs as well as Jurkat cells 
were incubated with 0.03µg/ml of phorbol myristyl acetate (PMA) (Sigma-Aldrich Co.), 
0.3µg/ml of ionomycin (Sigma-Aldrich Co.) and 1µg/ml of Recombinant Human B7 Fc 
Chimera (R&D systems); and treated with 0.02 µm filtrated (Anotop, Whatman, England) 
supernatants of virus infected PC3-MM2 cells. In the loss of function assay 0.1µg/ml of 
recombinant human CTLA-4/Fc Chimera (R&D Systems) was added to the previous 
stimulating and treated media. The next day after PBMC stimulation or two days after Jurkat 
cells stimulation, interleukin-2 (IL-2) or interferon-γ (IFN-γ) levels in the growth media were 
analyzed by BD Cytometric Bead Array Human Soluble Protein Flex Set (Becton Dickinson) 
according to the instructions of the manufacturer. PC3-MM2 cells were infected with 10 
VP/cell and 48h later the supernatants collected. Mouse anti-human CTLA-4 (=CD152) mAb 
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(BD PharmingenTM, Europe) was used as a positive control. FCAP Array v.1.0.2 (Soft Flow) 
software was used for analysis. 
3.4.11 Immunofluorescence flow cytometry (IV) 
Indirect immunofluorescent labeling was used by incubating cancer cells with primary 
antibody against human CTLA-4 (BD PharmingenTM, Europe) at 4ºC for 30 minutes, washed 
and incubated in the dark with secondary antibody at 4ºC for 30 minutes. Subsequently, 
fluorescence intensity was measured on a LSR flow cytometer (BD PharmingenTM, Europe). 
Clontech Discovery Labware Immunocytometry systems (BD PharmingenTM, Europe) and 
the FlowJo 7.6.1 software were used for analysis. 
 
3.4.12 Measurement of human IgG concentrations by Elisa 
Tissues were minced with a scalpel and incubated with 5 μl of protease inhibitor (P8340; 
Sigma-Aldrich, St Louis, MO) and 600 μl of digestion mixture consisting of RPMI 1640 
medium with 10 mmol/l HEPES buffer and 1.6 mmol/l phenylmethylsulfonyl fluoride (Sigma-
Aldrich), 40 μg/ml gentamycin (Amresco, Solon, OH), 100 μg/ml bovine serum albumin 
(Sigma-Aldrich) and 100 μg/ ml Zwittergent 3-12 (Merck4Biosciences, Darmstadt, Germany). 
After incubation of 90 minutes at 37 °C under continuous agitation the tumor lysates were 
subjected to 30 seconds of sonication and centrifuged at 2,000g for 10 minutes at 4 °C. 
Supernatants were collected and stored (Koski, Kangasniemi et al. 2010). Plasma was 
separated by centrifugation from blood collected by heart puncture. 
Human IgG concentrations in tissue lysate supernatants and plasma samples were 
measured using Elisa for Human IgG (Immunology Consultants Laboratory, USA) according 
to the manufacturer’s protocol. Total protein concentration was measured by BCA Protein 
Assay (Thermo Scientific Pierce) according to the manufacturer’s instructions. 
 
3.5 In vivo studies 
All experiments were approved by the Experimental Committee of the University of Helsinki 
and the Provincial Government of Southern Finland. Mice aged 4-5 weeks were purchased 
from Taconic (Ejby, Denmark) and quarantined for at least one week. The animals were 
frequently monitored for their health status and euthanized as soon as any sign of pain or 
distress was noticed.  
In all the present studies the tumor growth rate was assessed. For tumor volume 
determination, the largest diameter of the tumor and the diameter perpendicular to it were 
measured with calipers. Volumes were calculated using the formula: (larger diameter) x 
(smaller diameter)2 x 0.5.  
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3.5.1 Animals models in study I 
For the HNSCC cancer xenograft model, female NMRI nude mice were subcutaneously 
injected with 5x106 UT-SCC 8 HNSCC low passage tumor cell culture together with matrigel 
(BD Pharmingen, Franklin Lakes, NJ) in both flanks.  
 
3.5.1.1 Comparison of different transductionally targeted oncolytic adenoviruses 
When the HNSCC cancer xenograft tumors (n=10/group) reached a volume of ca. 80 mm3  
, they were randomized into 3 groups and injected for 3 consecutive days (days 0, 1 and 2) 
with the indicated vectors at a dose of 3x108 VP and control tumors were injected with 
growth medium only. 
 
3.5.1.2 Combination of oncolytic adenoviruses with chemotherapy, radiotherapy 
and monoclonal antibody against EGFR 
When the HNSCC cancer xenograft tumors (n=10/group) reached a volume of ca. 30 mm3, 
they were injected intratumorally with Ad.pK7-Δ24 (1 x 108 VP) on days 1, 4, 8 and 11. 
Cetuximab (750 µg), and/or chemotherapy (25 µg cisplatin+ 250 µg 5-FU) was given 
intraperitoneally on days 0, 3, 7 and 10. Whole body radiation (1 Gy) was given on days 0, 3, 
7 and 10. On day 97, the remaining tumors were collected and stored at -80°C.  
 
3.5.2 Animals models in study II 
For the prostate cancer xenograft model, NMRI nude mice were subcutaneously injected 
with 5x106 PC3-MM2 tumor cells in both flanks. Mice were randomized into 12 groups 
(n=6/group; tumor volume ca. 0.55 cm3): mock (injected with growth media only), 
rAdE1B55K, rAdE4orf3, rAdE4orf6, Ad5(GL), Ad300wt, with and without radiotherapy (RT). 
Intratumoral virus injections of 1x109 VP were administered every other day (total of 4x109 
VP). Fractionated whole- body irradiation was given every other day (4 x 2 Gy) during 8 
treatment days.  
 
3.5.3 Animals models in study III 
For the HNSCC cancer xenograft model, female NMRI nude mice were subcutaneously 
injected with 3x106 UT-SCC 8 HNSCC low passage tumor cell culture together with matrigel 
(BD Pharmingen, Franklin Lakes, NJ) in both flanks. After 7 days, the tumor bearing mice 
were randomized into 6 groups (n=8/group, ca. 25 mm3) tumors were injected 3 times every 
other day with the indicated vectors at a dose of 3x108 VP (days 0, 2 and 4) and control 
tumors were injected with growth medium only. 5-FC was given intraperitoneally at 250 
mg/kg/day for 3 times (from day 1 to day 11, from day 28 to day 38 and from day 48 to day 
56) and phosphate buffered saline (PBS) injections were used as negative controls.  
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3.5.4 Animals models in study IV 
For the prostate cancer xenograft model, NMRI nude mice were subcutaneously injected 
with 5x106 PC3-MM2 tumor cells in both flanks. After 7 days, the mice were randomized into 
5 groups (n=8/group, tumor volume ca.130 mm3),tumors were injected for 3 times every 
other day with 3x108 VP of the indicated vectors (days 0, 2 and 4) and control tumors were 
injected with growth medium only. 
 
3.6 Statistical analysis (I-IV) 
In all studies, statistical analyses were performed using a two-tailed Student’s t-test and/or  
the nonparametric Mann–Whitney U-test (SPSS 15.0, Chicago, IL). For all analyses a P 
value of <0.05 was considered statistically significant.  
In study I, combination index (CI) values were calculated using the Chou Talalay's median-
effect method (Chou T-C. 1983) under assumption of mutually nonexclusive drug 
interactions with S-PLUS 6.0 (Insightful Corporation, Seattle, WA). In CI analysis <1 
indicates synergism, 1= additivity, and CI >1 indicates antagonism. One-sample t-test was 
performed to determine whether the mean CI from separate experiments at multiple effects 
levels were significantly different from a value of 1.0. 
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4 RESULTS AND DISCUSSION 
 
4.1 High frequency of CD133+/CD44+ cancer initiating cells in HNSCC tumors 
recurr after anti-EGFR monoclonal antibody treatment (I) 
Currently, there is an increased clinical use of epidermal growth factor receptor (EGFR) 
inhibitors (e.g. cetuximab), which have shown utility in combination with chemotherapy, 
radiotherapy and chemoradiotherapy (Bonner, Harari et al. 2006; Nyati, Morgan et al. 2006). 
However, increasing evidence suggests that patients who initially respond to EGFR 
inhibitors may subsequently become refractory (Pao, Miller et al. 2005). Therefore, it is 
important to study the mechanisms of treatment resistance in order to further developments 
and improvements.  
Tumor initiating cells or cancer stem cells have been suggested to be a possible reason for 
tumor relapse to the current treatment modalities (Baumann, Krause et al. 2008; Prince and 
Ailles 2008). It has been proposed that current treatment modalities used for HNSCC and 
other cancer types may selectively kill differentiated cancer cells, producing tumor 
regression, while sparing tumor initiating cells, which can lead, in time, to tumor relapse 
(Baumann, Krause et al. 2008; Prince and Ailles 2008). In agreement with such reports, 
relapsed tumors to cetuximab were found to have higher ratio of CD44/CD133 positive cells 
in relation to EGFR positive cells (Figure 1, Study I), suggesting that cancer stem cells might 
play a role in the mechanism of resistance to cetuximab. In addition, EGFR inhibition is 
usually not effective enough to be of clinical benefit as a single therapy and the best 
responses are achieved in combination regimens (Bonner, Harari et al. 2006). Also, it has 
been reported that capsid modified viruses may be able to kill tumor initiating cells (Eriksson, 
Guse et al. 2007; Bauerschmitz, Ranki et al. 2008). This prompted us to study if a 
combination regimen with oncolytic Ad could be utilized to increase the therapeutic efficacy 
of standard cancer therapies such as monoclonal antibody therapy, chemotherapy and 
radiotherapy. 
 
4.2 Capsid modified adenoviruses exhibit increased gene transfer to HNSCC 
low passage tumor cell cultures (I) 
Clinical trials have revealed Ads as a promising tool against cancer as well as showing 
increased tumor targeting. Previous reports have demonstrated that transductionally 
targeted oncolytic viruses enter tumor cells through CAR-independent mechanisms (Ranki, 
Kanerva et al. 2007). This might be useful to overcome the inefficient transduction of many 
tumor types, especially when they are advanced due to variable or low CAR expression 
(Okegawa, Li et al. 2000). A panel of capsid modifications was tested in several HNSCC low 
passage tumor cell cultures in order to select which capsid modifications allowed increased 
gene transfer of human HNSCC and it was found that 5/3, pK7, RGD and pK7.RGD capsid 
modifications promote increased gene transfer when compared with the wild Ad5 capsid 
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(Figure 1, Study I). Furthermore, 5/3 and pK7 capsid modification promoted the highest 
gene transfer (Figure 1, Study I). Low passage tumor cell cultures might resemble patient 
tumors more closely than conventional cell lines (Erjala, Sundvall et al. 2006).  
 
4.3 Capsid modified oncolytic adenoviruses are effective in killing tumor 
cells both in vitro and in vivo (I, III, IV) 
Previous reports indicate that by deleting the Rb binding site of the E1A (Δ24), increased 
tumor targeting can be obtained (Kanerva, Zinn et al. 2003). Also, it has been reported that 
transcomplementally and transductionally double targeted oncolytic viruses have an 
enhanced anti-tumor effect both in vitro and in vivo in several different tumor types (Kanerva, 
Zinn et al. 2003; Raki, Kanerva et al. 2005; Ranki, Kanerva et al. 2007). In line with such 
reports, Δ24 transcriptional targeting in combination with 5/3 chimera or pK7 capsid 
modifications promoted increased cell killing of HNSCC low passage tumor cell cultures in 
vitro but only pK7 presented a significant anti-tumor effect in vivo (Figure 2, Study I). The 
high levels of heparan sulfate proteoglycan (HSPG) reported in HNSCC might explain the 
high efficacy of pK7 (Hussein and Cullen 2001). Furthermore, in vitro, Ad5/3-Δ24 was found 
to kill prostate cancer cells (Supplementary Figure 1, Study III and Figure 3, Study IV) as 
well as lung cancer and ovarian cancer (Figure 3, Study IV) confirming previous reports 
(Särkioja, Kanerva et al. 2006; Rajecki, Kanerva et al. 2007; Raki, Särkioja et al. 2008).  
 
4.4 Combination of oncolytic adenoviruses with chemotherapy, radiotherapy 
and/or monoclonal antibody treatment resulted in significantly increased  killing of 
tumor cells in vitro and complete tumor eradication in vivo (I) 
In order to test our initial hypothesis that the combination of oncolytic viruses with 
conventional HNSCC therapies has an increased antitumor effect, the most promising 
oncolytic viruses (Ad5.pK7-Δ24 or Ad5/3-Δ24) were combined with cetuximab, 
chemotherapy or radiotherapy, and the increased cell killing was assessed by MTS assay. In 
vitro data suggested that there was a positive synergistic effect between the virus and 
chemotherapy or radiotherapy when pair-wise analysis was performed (Figure 4, Study I), in 
accordance with previous reports (Khuri, Nemunaitis et al. 2000; Lamfers, Idema et al. 
2007). It is also worth to report that cetuximab, despite the poor results as a single agent in 
vitro (Figure 3, Study I), was observed to have a greater response in vivo. A possible 
explanation for these findings is that the Fc tail may activate the complement and antibody-
dependent cell-mediated cytotoxicity against the tumor (Bonner, Harari et al. 2006). Further, 
indirect effects on angiogenesis, invasion and metastasis may play a role in the in vivo 
effects of cetuximab (Vincenzi, Schiavon et al. 2008). The same reasons might also explain 
the modest results of the quadruple combination in vitro, although in vivo a complete tumor 
reduction was observed (Figure 5, Study I).  
According to this study, tumors relapsing after cetuximab are enriched in CD133 and CD44+ 
cells (Figure 1, Study I). Therefore, it is tempting to hypothesize that the quadruple 
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combination was able to kill these cells. This seems to be confirmed by the finding that 
tumors were completely eradicated by the quadruple combination and also, in vitro, all cells 
could be killed (Figure 5, Study I). Tumor initiating cells may be resistant to radiotherapy, 
chemotherapy and kinase inhibitors (Reya, Morrison et al. 2001; Dean, Fojo et al. 2005). 
Therefore, the oncolytic virus present in the quadruple combination may have been 
important with regard to complete tumor eradication. In particular, previous reports suggest 
that capsid modified viruses may be able to kill tumor initiating cells (Eriksson, Guse et al. 
2007; Bauerschmitz, Ranki et al. 2008). 
4.5 Infection with recombinant adenoviruses expressing the adenoviral 
radiosensitizing proteins E4orf6, E4orf3 and E1B55K prior to radiotherapy 
significantly increases tumor cell killing in vitro but only E4orf6 and E4orf3 were able 
to radiosensitize in vivo. (II) 
The radiosensitizing effect of oncolytic serotype 5 adenoviruses has been recently reported 
in vivo (Kim, Kim et al. 2009; Rajecki, af Hallstrom et al. 2009). Also, a synergistic effect was 
observed in in vitro experiments with HNSCC previously in this study (Study I). The Ad 
proteins E1B55K, E4orf3 and E4orf6 have evolved to inhibit cell cycle arrest and DNA 
double-strand break (DSB) repair signaling to maintain effective replication (Boyer, Rohleder 
et al. 1999; Stracker, Carson et al. 2002; Hart, Yannone et al. 2005; Carson, Orazio et al. 
2009) (section 1.3.1.1.1). In order to assess if the radiosensitization of tumor cells by Ad is 
mediated through the impairment of a DSB repair mechanism, replicative deficient viruses 
expressing the proteins E4orf6, E4orf3 or E1B55K were used. These viruses expressed high 
levels of the respective radiosensitizing proteins and are able to transduce prostate cancer 
cells with rates of more than 90% at 24h after infection (Figure 1, Study II).  
In vitro, prostate cancer, breast cancer and HNSCC cells infected with the E4orf6, E4orf3 or 
E1B55K expressing viruses and irradiated the next day showed increased cell killing in 
comparison with only irradiated cells or to cells irradiated and infected with replicative 
deficient control virus A5(GL) expressing GFP and luciferase (Figure 2, Study II). The best 
radio sensitizing effect was observed with the E4orf6 (Figure 4, Study II). Furthermore, 
double or triple combinations of the recombinant viruses did not further improve the cell 
killing of the most effective viral component alone (Figure 3, Study III). Despite this, there 
have been molecular level indications that E1B55K and E4orf6 as well as E1B55K and 
E4orf3 might work in complexes to inhibit the DSB repair (Leppard and Everett 1999; 
Mohammadi, Ketner et al. 2004; Schwartz, Lakdawala et al. 2008). 
In vivo, rAdE4orf3 was the most effective of the transgene expressing viruses when used 
with radiation, and resulted in significant reduction of tumor growth compared to Ad5(GL) 
with RT (Figure 5, Study II). Also, rAdE4orf6 with radiation resulted in a statistically 
significant reduction of tumor growth. In contrast, rAdE1B55K with radiation did not inhibit 
tumor growth. Replicative control wild type virus Ad300wt caused a significant reduction of 
tumor growth combined with RT but not alone. Interestingly, in line with this study and 
others’ in vitro results (Brand, Klocke et al. 1999; Kim, Kim et al. 2009; Wang, Sima et al. 
2009), recombinant viruses had anti-tumor efficacy even in the absence of radiation (Figure 
5, Study II).  
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 4.6 Infection with rAdE4orf6 and rAdE4orf3 results in persistence of double-
strand breaks at 24h post-irradiation. (II)  
Inhibition of DSB repair has been suggested to be the main mechanism contributing to the 
radiosensitizing effect of replication-competent adenoviruses (Stracker, Carson et al. 2002; 
Rajecki, af Hallstrom et al. 2009). In line with such reports, Ad300wt wild type virus showed 
50% persistence of DSBs 24h after irradiation as well as rAdE4orf3 or rAdE4orf6 (40-50%) 
(Figure 6, Study III), indicated by γH2AX foci. In contrast, the control virus Ad5(GL) or RT-
only casued fewer DSBs (10%, <5%, respectively). rAdE1B55K showed some persistence in 
DSBs (25%) (Figure 6, Study III). 
Despite rAdE4orf3 or rAdE4orf6 having revealed similar inhibition of DSBs repair compared 
to replicative competent wild type virus (Figure 6, Study III), in vivo the highest tumor growth 
inhibition was achieved by the replicative competent wild type virus in combination with 
radiotherapy (Figure 5, Study II). These findings support that gene transfer alone is not 
enough to achieve sustained an anti-tumor effect in vivo, but when combined with viral 
replication increased anti-tumor efficacy can be obtained. 
The MRN complex (Mre11, Rad50 and NBS1) is important in DSB sensing, stabilization, 
signaling, and repair (Rogakou, Pilch et al. 1998; Williams, Williams et al. 2007). It 
upregulates ataxia-telangiectasia mutated (ATM) and ATM-Rad3-related (ATR) signal 
transduction pathways (Rogakou, Pilch et al. 1998; Kuo and Yang 2008), which are involved 
in both homologous recombination and non-homologous end-joining (Lilley, Schwartz et al. 
2007). Earlier data suggested DNA-dependent protein kinase (DNAPK) inhibition as the 
main mechanism for E4orf6 and E4orf3 mediated DSB repair inhibition (Boyer, Rohleder et 
al. 1999). However, ATM/ATR pathway inhibition by E4 proteins is evident, although the 
specific targets remain unknown, and plays a more central role in DSB signaling (Rogakou, 
Pilch et al. 1998).  
 
4.7 FCU-1 fusion enzyme or anti-CTLA monoclonal antibody armed oncolytic 
and replication-deficient adenoviruses retain their efficacy of infecting tumor cells 
and express high levels of functional proteins in vitro and in vivo (III, IV) 
Clinical trials have demonstrated the increased anti-tumor effect when oncolytic Ads are 
combined with conventional cancer therapies (You, Yang et al. 2000; Xia, Chang et al. 
2004). In addition, Study I showed that transductionally and transcomplementally double 
targeted oncolytic Ad can also be combined with conventional cancer therapies such as 
radiotherapy, chemotherapy and monoclonal antibody treatment to achieve increased and 
even synergistic anti-tumor effects. These findings support that lower doses of conventional 
cancer therapies can be used in a multimodal approach to achieve an increased anti-tumor 
effect. The side effects of the treatments are nonoverlapping, which might facilitate 
increased efficacy without increasing toxicity. Furthermore, Study II supported the 
radiosensitization effect of Ad but as well the need to use viral replication to obtain a 
sustained anti-tumor efficacy. Therefore, in order to take advantage of the oncolytic Ad 
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synergy with conventional cancer therapies and further reduce possible side effects, double 
targeted oncolytic Ad was armed with FCU-1 fusion enzyme or anti-CTLA monoclonal 
antibody (Figure 1, Studies III and IV). Also, in order to further demonstrate the need of viral 
replication to achieve sustained anti-tumor efficiency, the isogenic replicative deficient Ad 
was produced (Figure 1, Studies III and IV). The newly produced viruses feature a 5/3 
chimera capsid modification and the oncolytic viruses additionally have a 24 bp deletion in 
the E1A (Δ24 transcomplementary targeting). All the viruses produced high levels of the 
respective proteins measured by Western blot (Figure 2, Studies III and IV).  
Viral expressed FCU1 enzymatic CDase and UPRTase activities were confirmed by the 
analysis of the enzymatic conversions of 5-FC to 5-FU and 5-FU to 5-FUMP in HPLC 
separation in vitro (Figure 2, Study III) and 5-FC to 5-FU in vivo (Figure 4 and 5, Study III). 
The highest FCU1 enzymatic activities were observed in cells infected with the oncolytic 
virus Ad5/3-Δ24FCU1 both in vitro and in vivo. Furthermore, chemotherapeutic 5-FU product 
of the 5-FC conversion was found only in the tumors treated with Ad5/3-Δ24FCU1 and 5-FC 
up to day 57. This finding supports the hypothesis that combined anti-tumor transgene 
expression to viral replication results in a sustained long term targeted anti-tumor effect. In 
fact, on day 57, increased apoptosis was observed in the tumors treated with Ad5/3-
Δ24FCU1 and 5-FC, resulting from the bystander effect of the FCU1 enzymatic conversion 
of 5-FC to the chemotherapeutic metabolites 5-FU and 5-FUMP (Figure 6, Study III). 
Virally expressed anti-CTLA4 mAb biological activity was confirmed by measuring the 
increased IL-2 production of stimulated Jurkat cells (clone 6.1) as described previously (Lee, 
Chuang et al. 1998). This analysis showed that mAb anti-CTLA4 activity was found in the 
supernatants of cells infected with Ad5/3-Δ24aCTLA4 and Ad5/3-aCTLA4 compared to the 
respective isogenic controls Ad5/3-Δ24 or Ad5/3Luc1-infected tumor cells (Supplementary 
Figure 1 and Figure 2, Study IV). Furthermore, when rCTLA-4 was added to the medium, 
the anti-CTLA4 mAb T cell stimulating activity was lost, confirming the specificity of the anti-
CTLA4 mAb produced (Supplementary Figure. 1 and Figure. 2, Study IV). In addition, 
tumors treated with Ad5/3-Δ24aCTLA4 showed increased IgG production correlated with 
increased apoptosis, confirming further that the production in vivo of functional fully human 
monoclonal antibody specific for CTLA-4 in cells infected with Ad5/3-Δ24aCTLA4 (Figure 4, 
Study IV). Finally, tumors infected with Ad5/3-Δ24aCTLA4 showed 43.3-fold (p<0.05) more 
anti-CTLA4 mAb in the tumors than in the plasma and 81-fold (p<0.05) more than tumors 
treated with the replicative deficient Ad5/3-aCTLA4. These findings are in line with Studies II 
and III in that increased transgene production can be obtained by combining transgene 
expression to viral replication  
Taken together, our data indicates that infection with Ad5/3-Δ24FCU1 or Ad5/3-Δ24aCTLA4 
leads to high expression of functional transgenes in targeted tumors. 
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4.8 Oncolytic adenovirus armed with a suicide gene system or 
immunomodulatory agent showed increased cell killing in vitro and tumor growth 
inhibition in vivo. (III, IV) 
Arming oncolytic viruses with powerful transgenes such as FCU1 + 5-FC suicide system or 
with anti-CTLA4 mAb has been previously a concern because of their size and biological 
properties. 5-FC enzymatic conversion by the FCU1 fusion enzyme results in the 
chemotherapeutic agent 5-FU and 5-FUMP, which interfere with DNA and RNA synthesis 
and consequently could inhibit viral replication. In fact, a certain decrease on viral copy 
number was observed when 5-FC was added to Ad5/3-Δ24FCU1 infected cells or tumors 
(Figure 3 and 6, Study III). Nevertheless, a significantly increased anti-tumor effect was 
observed when Ad5/3-Δ24FCU1 was combined with 5-FC than with component alone both 
in vitro and in vivo (Figure 3 and 4, Study III). The increased efficacy suggests that the 
additional cell killing and bystander effect provided by 5-FU and 5-FUMP, together with the 
putative synergy with oncolytic adenovirus (Study I), are more important than the relative 
reduction in virus replication.  
CTLA-4 blockade with mAbs results in increased production of IFN-γ and major 
histocompatibility complex (MHC) class I molecules that can potentially inhibit virus 
replication (McCart, Puhlmann et al. 2000; Nakamura, Mullen et al. 2001). However, this 
may not be a problem in tumor cells which are often deficient in interferon signaling and 
MHC-I presentation (Sherr 1996). Furthermore, the anti-CTLA mAb gene cassette brings the 
Ad5/3-Δ24aCTLA4 genome size close to the maximum 105%. Nevertheless, increased 
cytotoxicity was observed in vitro and increased anti-tumor efficacy in vivo (Figure 3 and 4, 
Study IV). The replicative competent control Ad5/3-Δ24 was not able to significantly 
increase the anti-tumor efficacy in this very aggressive prostate PC3-MM2 xenograft model 
despite similar cytotoxicity efficiency in vitro (Figure 3, Study IV). Also, the replicative 
deficient Ad5/3-aCTLA4 despite showing some cytotoxicity in vitro (Figure 3, Study IV), in 
vivo was not able to significantly reduce the tumor growth (Figure 4, Study IV). Ad5/3-
aCTLA4 cytotoxicity in vitro can be explained by increased tumor cell apoptosis mediated by 
the anti-CTLA4 mAb (Figure 4, Study IV). These findings, together with the increased 
apoptosis, indicate that oncolytic adenoviruses can effectively target the expression of 
functional anti-CTLA4 mAb in high amounts, resulting in increased anti-tumor efficacy. 
Furthermore, the main anti-tumor effect of the anti-CTLA4 mAb is mediated by the activation 
of the immune system against the tumor. However, this promising mechanism of action 
could not be tested in vivo because the human anti-CTLA4 mAb does not work in mice 
(Hanson 2004). 
4.9 Effective immunomodulation of cancer patient T-cells by anti-CTLA4 
monoclonal antibody expressing viruses and the effect of anti-CTLA4 monoclonal 
antibody on PBMCs from healthy individuals (IV) 
With the inability to fully assess the anti-tumor efficacy of the anti-CTLA4 mAb in mice and to 
extend Study IV preclinical findings into humans, PBMCs of patients with advanced solid 
tumors refractory to chemotherapy were simulated as previously indicated (Lee, Chuang et 
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al. 1998) (Figure 5, and rationale in Supplementary Figure 1, Study IV). In all four patients, 
supernatant from anti-CTLA4 mAb expressing viruses was able to increase T-cell activity, as 
measured by IL-2 and interferon gamma (Figure 5, Study IV). Similar data were obtained in 
a loss function assay (Suppl. Fig 2, rationale in Suppl. Fig 1, Study IV). However, in healthy 
donors, no significant immunomodulation was observed with supernatant from Ad5/3-
Δ24aCTLA4 infected cells but some immunomodulation was achieved with a high 
concentration of the positive control mAb. These findings support the suggestion that cancer 
patients have a higher degree of immunosuppressive processes ongoing due to the 
advanced tumor present (Figure 1 and (Stagg, Johnstone et al. 2007)), thus requiring lower 
concentrations of anti-CTLA4 mAb to activate T cytotoxic cells. 
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5 SUMMARY AND CONCLUSIONS  
The overall goal of this thesis was to improve treatment options for HNSCC and prostate 
cancer using oncolytic adenoviruses. 
In study I it was found that cetuximab relapsed tumors have a higher proportion of cancer 
stem cells. In vitro studies revealed that Ad5.pK7-Δ24 and Ad5/3-Δ24 are the most promising 
capsid modifications for the treatment of HNSCC. Furthermore, the quadruple treatment 
modality using the double targeted Ad5.pK7-Δ24 with radiotherapy, chemotherapy and 
cetuximab mAb therapy was able to completely eradicate HNSCC xenograft tumors. Further, 
the low LC50 values obtained with the quadruple combination in vitro support that lower 
doses of therapeutic agents can be used in this modality and consequently with fewer 
possible side effects. 
Study II brought some light onto the mechanism of how Ads radiosensitize tumors. Data 
shows that endogenous adenoviral proteins E4orf3 and E4orf6 can sensitize prostate cancer 
cells to radiotherapy in vivo. Further, multiple administrations of adenovirus together with 
fractionated radiotherapy can restrict aggressive prostate tumor growth.  
The mechanisms of augmented therapeutic effects obtained by combining oncolytic 
adenoviruses, EGFR inhibitors, chemotherapy and radiotherapy require further studies. 
Nevertheless, our data together with others allow several hypotheses to be put forth. 
Cultured cells treated with ionizing radiation show increased levels of phosphorylated EGFR 
(Schmidt-Ullrich, Valerie et al. 1996) with subsequent EGFR import to the nucleus, where it 
activates the DNA-protein kinase (DNAPK) leading to DNA repair such as DSBs (Figure 5, 
Study II) and cell survival (Schmidt-Ullrich, Mikkelsen et al. 1997). Tumor cells treated with 
various cytotoxic drugs (e.g. cisplatin and 5-FU (Van Schaeybroeck, Karaiskou-McCaul et al. 
2005)) also promote EGFR phosphorylation in order to enable cell survival. Cetuximab 
inhibits radiation-induced activation of DNAPK, as well as EGFR nuclear import, DNA repair 
and survival from radiation induced damage (Dittmann, Mayer et al. 2005). The adenoviral 
protein E4orf6 enables prolonged auto-phosphorylation of DNAPK after ionizing radiation. 
This inhibits damage repair and reduces cancer cell survival (Hart, Yannone et al. 2005). In 
Study II, E4orf3, and to a lesser extent E1B55K, promoted delayed DSBs repair possibly via 
ATM/ATR or DNAPK (Rogakou, Pilch et al. 1998; Boyer, Rohleder et al. 1999). It has also 
been shown that adenoviral E1A gene products can inhibit HER-2/c-erbB-2 expression (Yan, 
Chang et al. 1991) for further inhibition of the erbB signaling pathway already partially 
blocked by cetuximab. Cetuximab and adenovirus use different ways to inhibit the activation 
of the erbB survival pathway. This might make it more difficult for tumor cells to overcome 
pathway inhibition for gaining resistance to chemo and radiation regimens. 
To take advantage of the synergistic effects between double targeted oncolytic Ad with 
chemotherapy and mAb observed in Study I, Ad5/3-Δ24FCU1 and Ad5/3-Δ24aCTLA4 were 
produced. Ad5/3-Δ24FCU1 with 5-FC seemed to result in improvements in anti-tumor 
activity (Study III). Ad5/3-Δ24aCTLA4 to our knowledge, is the first study showing that a full 
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length mAb can be produced from an oncolytic adenovirus. Also, it is the first fully human 
anti-CTLA4 mAb expressed by a tumor targeted replicative competent platform that resulted 
in improved anti-tumor activity (Study IV). No side effects were observed in these 
experiments, but this requires further studies. Also, these viruses confirm the hypothesis that 
arming tumor targeted oncolytic viruses with potent anti-tumor transgenes results in high 
tumor concentrations and low systemic concentrations of the transgenes. The anti-tumor 
potency of both these viruses’ might be further improved by combining them with radiation 
(Studies I and II) 
The data in these studies provide a rationale for the clinical translation of Ad5/3-Δ24FCU1 
and Ad5/3-Δ24aCTLA4 as two new oncolytic viral vectors for treating HNSCC and PC. Since 
the p16-Rb pathway is defective in many if not all solid tumors (Sherr 1996), Ad5/3-
Δ24FCU1 and Ad5/3-Δ24aCTLA4 are attractive candidate agents for treatment of many 
other types of cancer that are refractory to available treatments. 
However, clinical trials are needed to confirm the data in humans. Recent breakthroughs in 
clinical gene therapy have demonstrated that small incremental improvements have the 
potential for large differences to patients. Often, these advances have been achieved 
through combination therapies (Ylä-Herttuala 2008; Aiuti, Cattaneo et al. 2009). 
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